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ABSTRACT 
Perkins, Jessica L. BIOFUNCTIONAL COATINGS USING DIRECT-WRITE 
FABRICATION TECHNIQUE FOR SURGICAL IMPLANT DEVICES. (Major 
Professor: Dr. Salil Desai), North Carolina Agricultural and Technical State University. 
 
 Surface modification of biomaterials is of critical value to attain desired 
functionality of biomedical devices and implants. Many of the conventional 
manufacturing methods used for the fabrication of thin film coatings lack the ability to 
precisely dispense biological compounds without compromising its chemical integrity. 
This research investigates the use of direct-write inkjet technique for the deposition of 
multi-layer coatings of biodegradable polymers. The Direct Write inkjet method provides 
selective deposition and patterning capability for depositing multi-material coatings on 
biomaterials for a vast array of surgical implant devices (e.g. stents for cardiovascular 
applications and orthopedic implants).  
 In the first phase of the research, an elastomeric polymer, namely polyester-
urethane urea (PEUU) was used to encapsulate an anti-proliferation drug paciltaxel 
(Taxol). The direct-writing process was employed to coat multiple layers of this 
polymeric formulation on a model titanium alloy surface. Characterization experiments 
were conducted to observe the influence of drug dosage and coating thickness on the 
release kinetics of the multilayer coatings. Drug release kinetics were characterized using 
an ultraviolet-visible spectrum (UV-Vis) spectrophotometer and surface morphology was 
assessed using optical microscopy and scanning electron microscopy (SEM). 
Biocompatibility tests were conducted to assess the smooth muscle cell inhibition and 
platelet adhesion properties of the coatings.  The effects of drug dosage and layer 
  
thickness were evaluated via statistical significance tests. Tunable drug release coatings 
can be developed for an intended application by manipulating a given set of input factors. 
In the second phase of the research, the direct-write printing process was utilized 
to deposit precise layers of multilayer polymeric coatings on magnesium alloy surface. 
Biodegradable magnesium alloys provide substitutes for permanent metal implant 
materials such as titanium or stainless steel. Polymeric coatings provide a barrier layer 
that can retard the corrosion process of the magnesium alloys for vascular and orthopedic 
applications. Poly(lactic-co-glycolic acid (PLGA), polycaprolactone (PCL),  and PEUU 
were chosen based on their varying degradation properties. Immersion studies were 
conducted in a simulated body fluid (SBF) to determine the corrosion behaviors of 
different sample types using inductively coupled plasma spectroscopy (ICP).  
Biocompatability tests such as the lactate dehydrogenase (LDH) assay were conducted to 
assess the cytotoxicity levels induced from magnesium ion exposure.  A reduction in 
magnesium ion content was observed from the polymer-coated samples.  Findings also 
showed correlation between the release of the magnesium alloy and the health of normal 
human bronchial epithelial cells evaluated using the COX-2 gene expression.  This 
research establishes a foundation for identifying candidate polymer coatings to control 
the corrosion of magnesium alloys.   
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CHAPTER 1 
INTRODUCTION 
1.1 Overview 
The design of newer and more effective drug delivery systems have begun to 
emerge in the field of biomedical engineering, specifically pertaining to the development 
of biodegradable and bioabsorbable implant materials. Developments in metal alloying 
and surface modification processes are at the forefront of many research endeavors where 
the intent is to develop revolutionary biomaterials.  Concurrently, the study of temporal 
and spatial release kinetics of pharmaceutical reagents from drug-eluting surgical devices 
such as cardiovascular and tracheal stents and orthopedic implants is of growing interest 
[1-4].   Surface modifications via different coating techniques, can be applied to various 
biomaterials to enhance their biocompatabily and thus enhance their effectiveness in 
treating the various post operative effects associated with surgical implant procedures [5-
9].   
The use of metallic biomaterials for biomedical applications requires that a 
number of conditions be met.  The material must be biocompatible and corrosion resistant 
so as not to release undesired metal ions into the body [10].  It must posses an adequate 
mechanical strength, thus eliminating potential for fracture and must be free of toxic 
response within the body or host site [11].  Some commonly known materials used for 
fabrication of metallic stents include stainless steel [11], nickel [14], titanium alloys [10-
11], iron, and magnesium alloys [10-14].  Similarly, silicone and certain polyurethanes 
have been used for fabrication of cardiovascular and thoracic devices due to their 
2  
favorable biocompatible properties [15].  A comparison of the various implant materials 
with their respective advantages and disadvantages is provided herein.   
1.2 Biomaterials for Implant Manufacturing  
The most common stent materials include metallic, polymer, and silicone [15].  
Of the metallic group, materials can be further cateragorized into those that are toxic, 
non-toxic and bioinert, non-toxic and bioactive, and non-toxic and bioabsorbable [16].  
Metallic materials which have already been accepted for use as surgical implant materials 
such as stainless steel and titanium are considered as non-toxic, bioinert materials as they 
do not release any immediate toxic ions into the body, however materials in this category 
may result in the death of surrounding cells or tissues over time [17].  This is depicted in 
Figure 1.1.  The Wallstents generally used today are manufactured using these non-toxic, 
bioinert materials.   
 
Figure 1.1 L. Henchs' catergorization of tissue implant responses 
3  
The metallic stent (or Wallstent) generally consists of a wire-like, criss-cross, 
stainless steel mesh having a tubular shape and offers the mechanical strength necessary 
to prevent restenosis, or collapse of the arterial wall, after angioplasty [18].  The diameter 
of the metallic stents’ outerwall is also thinner, allowing for a larger inner diameter and 
increased blood flow through the arteries.  Another important advantage is the lack of 
migration that occurs once the device has been placed.  In contrast, the silicone design 
has a rather narrow inner diameter due to its thicker outer wall and issues with migration 
and dislodging have been observed [19].   
Disadvantages of the metallic, mesh-like design is that it is generally permanent 
due to partial or full integration into the airway or arterial wall, making the removal 
process difficult whereas the silicon stent is easily removable and may be exchanged 
frequently [19].  Environmental factors that inhibit the effectiveness of metallic tubular 
supports include in-stent granulation tissue formation, inflammatory disease, smooth 
muscle cell migration, stent thrombogenicity, and neointimal hyperplasia [20].  The 
presence of these factors are more prominent when bioinert materials are employed.  
Thus, they are identified as a foreign body object within the physiological environment 
and become encapsulated within a fibrous mesh.  Subsequently, this can bring about 
increased external forces causing the tubular mesh to collapse, also referred to as 
restinosis [21].  With the transition from bioinert to biodegradable and bioabsorbable, 
more and more research scientist are beginning to focus on magnesium and its alloys as 
ideal candidates for surgical implant materials.   
4  
Magnesium is the fourth most abundant mineral found in the body, thus it is 
necessary in order for the body to remain in good health [22].  What makes magnesium 
such the ideal candidate for surgical implant materials is its ability to perform an intended 
function, degrade and become absorbed by the body without leaving any trace or toxic 
effects [23].  In a study conducted on atherosclerosis risk in communities, the authors 
suggests that there exists a connection between patients who suffer from cardiovascular 
disease and magnesium deficiency [24].  Thus magnesium-based, bioabsorbable stents 
are of increasing interest for patients suffering from heart disease.  
 
Figure 1.2 Depiction of matching Mg degradation and bone growth processes  
Magnesium is also an ideal candidate for orthopedic implant devices for bone 
growth and fracture repair due to it similar mechanical properties to bone.  The material 
offers such advantages as more physiological and less invasive repairs, possibility of 
tissue growth, temporary support during tissue recovery, and gradual dissolution by the 
physiological environment after it has performed its intended purpose.  However 
magnesium alone tends to degrade at an accelerated pace in saline environments thus not 
5  
allowing enough time for the device to perform its intended purpose.  A depiction of this 
concept is shown in Figure 1.2.  Recent research being conducted at the Engineering 
Research Center for Revolutionizing Metallic Biomaterials has applied various metal 
alloying and surface modification techniques to control the corrosion of magnesium. 
In addition to the use of magnesium alloys for implant and stent manufacturing, 
these materials can be coupled with a multi-functioning polymeric coating that can 
extend magnesium corrosion rates long enough for the stent to serve its purpose as well 
as administer any necessary therapeutic drugs. These coatings also add several other 
benefits, which are described further in the upcoming sections.   
1.3 Polymers for Stent Coating  
Over the past decade researchers have examined a number of ways in which 
pharmaceuticals can be transported via stent-mediated drug delivery methods.  Some of 
the methods found in literature range from synthetic and organic biodegradable polymers 
to non-degradable polymers.  The perusal of non-degradable polymers for biomedical 
uses led to less than satisfactory results for stent coating applications [25].  It is believed 
that the presence of the foreign body causes inflation and infection at the implant site, 
thus magnifying an already complex situation.  Biodegradable polymers were studied for 
stent coating as they offered a decrease in the number of surgical procedures required for 
device removal and a significant reduction in the number of restinosis cases [21].  
Contrasting studies from other cases, however, claim that the use of polymers in general 
may be incompatible with the blood thus increasing the risk of thrombosis. This 
6  
conclusion caused experts to investigate other alternatives for achieving localized drug 
delivery using stents.   
The uses of degradable polymers as a mechanism for drug delivery was revisited  
(after considering a number of other coating materials and their associated effects).   
Materials  such as Sirolimus [26,28], Paclitaxel (Taxol) [25-28], and Phosphorylcholine 
(PC) have been used to directly coat bare metal stents (BMS).  In some cases these 
materials were used as mechanisms for the entrapment of other medicines within 
themselves.  The use of PC has been used as a binding mechanism to carry drugs to 
treatment sites [29].   
The employment of non-polymeric coatings showed great promise in the fact that 
in most cases 100% efficacy was observed in terms of the intended amount of drug 
required for healing [25-28].  There was, however, an essential limitation of this method.  
The rate at which these substances were released ranged from around 60% to 80% in the 
first two or three days with subsequent elution of the remaining drugs releasing over the 
next 28 to 35 days [30].  This phenomenon is commonly called as a burst effect or initial 
burst period.  However, a procedure for mediated delivery of pharmaceuticals over 
extended periods of time was desired.   
1.4 The Model Stent 
The model stent design would be one that contains select properties of both the 
metallic and biopolymer tubular support systems.  The selected material for stent 
manufacturing would be bioabsorbale, having the ability to dissolve into the surrounding 
tissue without toxic effect.  The metallic wire mesh covered with a biodegradable 
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polymer would offer the mechanical strength required to maintain an open airway or 
blood vessel and allow for a higher blood flow rate (cardiovascular).  A thin biopolymer 
coating would not only add a second dimension to the stenting device as a protective 
barrier to increase the time span in which the stent remains operative, but could also serve 
as a drug carrying device.   
In addition to the increased functionality of tubular support structures following 
coating and/or polymeric surface treatments, more case specific advantages are realized.   
For example, late-stage lung cancer patients facing acute tracheal restenosis due to the 
rapid in-growth of a malignant tumor would require rapid, site-specific, chemotherapeutic 
sessions over an extended period of time.  Local delivery of a drug to the cancerous site 
via a polymer-coated stent can reduce the exposure of toxins to the body, thus ridding the 
impaired site of only the unwanted cells.  Also, the polymer matrix grants sustained 
treatment over time, eliminating the need for repetitive surgical procedures and their 
associated risk as well as substantial medical costs [31].  Literature suggests that a 
biodegradable polymer matrix containing drugs such as Palcitaxel and Sirolimus, which 
inhibit the migration and proliferation of smooth muscle cells, could be used as a 
mechanism for treatment of neointimal hyperplasia [32].  
The study of sustained drug release has important implications in the biomedical 
arena.  Research in the field of tissue engineering has integrated the theory of sustained 
release to deliver Nerve Growth Factors (NGF) encapsulated in polycaprolactone (PCL) 
to preserve bioactivity for the construction of biofunctional tissue scaffolds [33].  
Sustained release of NGF was achieved for three months [33].  Research scientists at the 
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Wake Forest Institute of Regenerative Medicine have achieved sustained release of 
oxygen ions to facilitate cell survivability during the brief period between the 
implantation of tissue engineered organs and the establishment of neovascularization 
where eventual tissue and cell necrosis may occur [34]. 
The above-mentioned applications have demonstrated the success of achieving 
prolonged periods of release for biomaterials having a single polymer matrix layer in 
which the resulting release profiles are a function of degradation properties of the 
biopolymer (carrier) and the rheological properties of the eluting substance (drug). 
Careful consideration of controllable factors such as polymer type, layer thickness, 
drug/agent use, and spatial distribution can result in distinctly, defined temporal release 
patterns.   
1.5 Coating Technologies 
A number of technologies have been applied for the deposition of polymer thin 
films onto metallic substrates, each having their own advantages and disadvantages.  
Techniques such as sputter deposition use a physical vapor deposition (PVD) process, 
which involves the bombardment of the targeted coating material followed by the 
evaporation and transportation of the evaporated material to a particular substrate.  
Sputtering offers great surface adhesion properties, a variety of grain sizes and 
orientations, and easy control of coating thicknesses. This process usually takes place 
inside a vacuum with line of site deposition making it difficult to coat substrates, such as 
stents, designed with undercuts and special features [35].  An important limitation with 
this process is the restricted amount of control over the vaporized coating material as 
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they are transported to the substrate resulting in wasted material.  Lastly, some of the 
targeting coat materials are susceptible to premature degradation due to the ionic 
material used during the bombarding process [35].   
The electro-spinning and -spraying techniques both use electricity, or an applied 
voltage as the source for carrying out deposition processes.  The electro-spinning 
requires a high voltage to be applied to the coating solution, which has been previously 
loaded into a spinneret [39].  Once a voltage is applied to the spinneret it is subjected to 
a whipping motion and a continuous jet is ejected.  This continuous jet is collected on an 
oppositely charged substrate.  This process is more appropriate where a mesh-like 
coating with high porosity is desired. 
Dissimilarly, the continuous jet emitted from a stationary metallic or glass 
capillary during the electro-spraying process is subject to electrostatic forces, which 
result in a cloud of positively charged particles.  The particles are then deposited onto an 
oppositely charged substrate [36-39].  Both the electro-spinning and spraying processes 
are able to deposit highly porous films using a variety of different materials.  They each 
have displayed high tensile strength and tunable mechanical and degradation properties.  
Neither of the two methods requires the use of heat, making them ideal for the use of 
biomaterials.  However, they do result in high amount of wasted materials and lack 
precision abilities for patterning.   
 The dip coating and spin coating deposition processes are less complex yet they 
provide a more uniform coatings.  The dip coating process is good for coating more 
complex structures and has a high deposition and processing rate [40].  This process, 
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however, does not provide variance as far as spatial control and is also inflexible in terms 
of switching out coating materials.  The spin coating process is also an extremely fast 
paced process, however it is limited to possessing only one substrate at a time.  It also 
lacks in the areas of material efficiency (only two to five percent of deposited material 
left on the substrate), repeatability, and thin film deformity.  Lastly, this technique cannot 
accommodate the need for coating two or three-dimensional structures [41].   
A newer and more complex technique is one known as Layer-by-Layer self-
assembly [42-44].  This is a process in which thin films are deposited by alternating 
layers of positively and negatively charged coating materials incorporating a wash step 
in between. This technique might offer a high degree of controlled thickness (atomic 
thickness), ability to coat a variety of materials such as biomaterials, the coating of 
difficult geometries.  In contrast, this method also has its limitations.  This process 
produces excess film build up, hence the need for a washing process in between layers 
and further study is required regarding the reaction between the charges coating 
materials and blood containing ions and polyelectrolyte (proteins).  This process is 
usually performed in combination with another deposition method (e.g. dip coating, 
spraying) and so one might also notice some similar advantages and limitations to those 
already discussed [42-44]. 
As implicated, all of the processes mentioned allow for the manipulation of 
coating thickness and surface morphology to some degree, therefore providing some 
control over the fabrication procedure.  Each process is capable of depositing varying 
types of materials such as metallics, polymers, and other organic materials for a range of 
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different applications.  It has also been noted that the achievable film (or layer) depth for 
this set of deposition processes range from atomic to nano thicknesses. Though the 
aforementioned techniques all possess some desired features of a deposition process to 
be utilized for the manufacture of biodegradable coatings, they all commonly lack the 
ability to deposit precise and localized coatings of three-dimensional complex structures.   
Inkjet printing techniques have been studied and applied as a method of drug 
delivery.  The technique produces droplets of ink through a jetting process via a small 
aperture, such as a nozzle or glass tip, onto a media.  Inkjet printing can be achieved 
using either of two methods [45].  The first, being continuous inkjet printing process.  
Continuous inkjet printing yields a continuous stream of ink that is broken down into 
droplets of uniform size and spacing.  An electric charge is selectively applied to the 
droplets passing through an electric field and are retained and recycled into the system, 
whereas the droplets free of the electric charge are deposited onto the media to form and 
image [45].   
1.6 Drop-on-Demand Inkjet Printing Technologies 
 More appropriately used is Drop-on-Demand (DOD) Inkjet printing process.  This 
method produces droplets of ink as they are needed as opposed to a continuous stream.  
The need for electrical charge in a magnetic field as well as the complex and unreliable 
recirculation systems required in the Continuous Inkjet System are eliminated, making 
this system more desirable for coating of complex structures (picoJet technology).  
Jetting is observed through one of the following approaches: thermal, piezoelectric, 
electrostatic, and acoustic.  The two most popular are thermal and piezoelectric.   
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The piezoelectric method is named after the deformation ability of the 
piezoceramic material used in the inkjet device.  In it there are four different methods in 
which the piezoceramic material can function.  The four methods include squeeze, bend, 
push, and shear.  Squeeze mode ink jet can be designed with a thin tube of piezoceramic 
surrounding a glass nozzle. In a typical bend mode design, the piezoceramic plates are 
bonded to a diaphragm forming an array of bilaminar electromechanical transducers. In a 
push mode design as the piezoelectric rods expand; they push against the ink to eject the 
droplets. The shear mode design deforms the piezoelectric against ink to eject the 
droplets. In this case the piezo becomes an active wall in the ink chamber. Interaction 
between ink and piezoceramic is one of the key parameters of a shear mode print head 
design.  For the purposes of this research, the piezoelectric approach would be more 
suitable as the thermal approach is expected to alter the properties of the biological agents 
used [45-48].   
1.7 Research Objectives 
This dissertation focuses on the application of a novel surface modification 
technique for developing functional coatings for metallic biomaterials.  Inkjet printing 
offers several advantages such as the capability to produce coatings on extremely 
complex structures, deposition onto the outer surfaces only, and flexibility to change 
coating design and materials.  This technique also allows for the adjustment of coating 
thickness with the objective of obtaining desired release patterns.   
Direct write inkjet printing techniques were used develop multilayer coatings 
laced with a pharmaceutical reagent for the purpose of studying controlled release 
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kinetics.  The coatings types were varied in concentration and thickness to determine how 
manipulating the two would affect the drug release profile.  The reagent chosen, 
Paclitaxel, has been proven to inhibit accelerated cell proliferation in cancerous 
environments, thus biological testing was conducted to relate the drug release profiles to 
cell inhibition.  Hemocompatability test were also conducted to relate drug release to 
blood coagulation on the functionalized surfaces.   
In a second study, the direct write techniques were used to develop polymer 
coatings that would aid in corrosion retardation of magnesium alloys for orthopedic and 
vascular applications.  It was believed that by manipulating droplet sizes and pitch 
distance as well as polymer type and thickness, that desirable corrosion rates based upon 
a given application could be obtained.  Cell viability and surface interaction of the 
magnesium alloy and various coating types were also explored.  The main objectives of 
this research are plainly stated: 
1. Develop controlled release coatings using direct write inkjet technologies. 
2. Study the relationship of drug release profiles to cell growth inhibition and 
hemocompatability of coated and uncoated metallic surfaces. 
3. Develop polymeric coatings for corrosion retardation of magnesium alloys using 
direct write inject technologies. 
4. Assess the corrosion behavior magnesium alloys (AZ31) with modified coating 
surfaces. 
5. Assess the cell viability and biocompatibility of Normal Human Bronchial 
Epithelial cell after controlled magnesium exposure. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Surface Modification and Functionalization 
The surface modification and functionalization of metallic materials is being 
proven to be an essential step in making materials more biologically compatible with the 
human physiological environment. Its relevance has become intensely important in the 
medical field as different materials are explored for their use and performance in the 
development of transplant and surgical devices.  As the need for more biocompatible 
surfaces arise, research scientist have began to focus their efforts on ways to enhance the 
physical, chemical, and biological properties of surfaces which they do not originally 
possess.  The uses for multi-functional surfaces can increase the life span of implant 
devices and reduce the need for surgical procedures.   
A number of processes that are employed for use in surface modification 
procedures are explained.  These procedures are necessary to inhibit the profound 
environmental reactions to surfaces causing wear, corrosion, and fatigue.  Biochemical 
modification through physical vapor deposition [49], self-assembly modification [50], 
and radio frequency glow discharge [51] are a few of the most popular techniques used.   
Ferretti et al.  argued that the advancement of self-assembled monolayers (SAM) 
could be sufficiently used for the development of monomolecular layered bionsensor 
devices [52].  By fabricating layers of biomolecular agents, which could simulate 
reactions with natural bodies, these devices could eventually be used to facilitate natural 
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functions [52].  An in depth review of processes to be used for this application 
accompanied by the advantages and disadvantages of each were described.   
With an effort to improve thromboresistance, or blood compatibility, of a titanium 
alloy (TiAl6V4) for ventricular devices, recent research efforts have been focused on 
possible chemical surface modification techniques [53].  A silane-coupling agent (APS) 
was used to covalently attach a phospholipid polymer (PMA) through radio frequency 
glow discharge.  The coupling agent was used to tightly bond together the PMA to the 
titanium alloy, where typically a reaction would not occur.  PMA was chosen due to its 
excellent ability to reduce platelet adhesion and coagulation of the blood at the medical 
implant site [53].  Modification of the Ti alloy surface added functionalization to the 
surface, which would have otherwise been biologically incompatible.  Characterization 
by X-ray photoelectron spectroscopy showed success of the surface modification 
procedures and thereby a reduction in adsorption of ovine sheep blood platelets [53].   
2.2 Controlled Degradation of Magnesium for Surgical Implant Materials 
 Towards the study of Magnesium (Mg) and its alloys for its application in implant 
materials, it has been noted that the material exhibits excellent biocompatible properties 
(similar to that of the bone structure) [54].  Its high tensile and yield strength as well as 
its density makes it an ideal material for biomedical implant devices [54].  However, its 
position on the galvanic chart is an undeniable indication of its susceptibility to corrosion 
in certain environments.  Several studies have been conducted in efforts to control the 
corrosion rates of magnesium-based implants long enough for the device to carry out its 
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intended purpose.  Two of the major mechanisms found in literature include metal 
alloying and surface modification for controlled degradation of magnesium.   
2.2.1 Alloying for Controlled Degradation of Magnesium 
 In a recent study, Gu et.al. studied the in vitro corrosion and biocompatibility of 
binary magnesium alloys.  Nine binary magnesium alloys containing 1% weight, X, of a 
proposed alloying component (X=Al, Ag, In, Mn, Si, Sn, Y, Zn, Zr) was tested for their 
potential use as biomedical alloying materials [55].  Each of the proposed materials was 
subjected to preliminary testing to characterize its microstructural and tensile properties.  
Electrochemical and immersion tests were conducted to understand corrosion potential of 
each material.  Finally, cytotoxicity and hemocompatibility test were conducted to 
determine the suitability of the materials for more specific biomedical applications (e.g. 
bone and blood vessel related cellular responses).  Gu et. al were able to conclude that 
Mg-Al showed positive response for nearly all of testing [55].   
 Aluminum as a potential magnesium-alloying candidate showed improved 
strength of the material, reduced corrosion, acceptable cell viability and toxicity on 
fibroblast, osteoblast and blood vessel cells.  However, other recent studies have proven 
aluminum to have neurotoxicant effects which have been associated with such 
neurological disorders as dementia, senile dementia, and Alzhiemer disease.  In the same 
study zinc, as major magnesium alloying component, also showed similar and favorable 
characteristics as aluminum [55].   
 In another study conducted at the Laboratory of Metal Physics and Technology, 
scientist proposed two new Mg-Y-Zn alloys (ZW21 and WZ21) for use as implant 
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materials for blood vessel repair (Hanzi et al, 2010).  The study focused on in vitro and in 
vivo electrochemical and biological responses through electrical impedance spectroscopy 
and standard immersion testing [56].  New alloys were compared to the first generation 
ZQ30 (Mg-Zn alloy) and a reference alloy, WE43 (Mg-Y-RE alloy) to characterize grain 
structure, corrosion potential, and degradation performance [56].  This reference alloy has 
been used in clinical trial settings as a stent was developed from this material and inserted 
into the aorta of a newborn patient.  Upon characterization of the proposed alloys, the 
authors conducted animal testing in which sample disks of the WZ21 alloy (chosen 
because of its more favorable mechanical performance) were implanted into two 
Gottingen minipigs.  The samples and surrounding tissues were extracted after 27 and 91 
days and results proved that there was a significant reduction in foreign body reaction 
activity after more extended implant periods [56].    
 Many efforts have been made to develop magnesium alloy specifically for bone 
regeneration and repair.  Li et al. propose a binary Mg-Ca alloy for use as biodegradable 
materials with the bone structure [57].  In this study Mg-Ca alloys of various calcium 
percentages (Mg-1Ca, Mg-2Ca, Mg-3Ca) were tested to determine structural and 
mechanical advantages to bone repair and its potential environmental behaviors.  
Immersion tests proved that the Mg-1Ca samples were protected from increasing 
corrosion rates due a protective layer formed on its surface from the electrolyte solution.   
 The findings of the preliminary mechanical and immersion tests led the authors to 
select Mg-1Ca to conduct further cytocompatibility and animal testing [57].  Mg-1Ca 
pins were manufactured and implanted into the left femoral shaft of 18 New Zealand 
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rabbits.  The pins were removed after one, two, and three months and characterized by 
weight and degradation.  Results showed that the pin had completely dissolved at three 
months post operation and that newly formed bone was detected using radiographic 
examination.  However, the issue of premature degradation still remains and further effort 
must be made to synchronize rate of degradation with the rate of bone formation [57].   
2.2.2 Surface Modification for Controlled Degradation of Mg Alloys 
The research group at the Tsinghua University in Beijing, China reports that the 
appropriate application of surface modification techniques can be employed to increase 
corrosion resistance of Mg and Mg alloys, thus making this material one that could be 
used for bone replacement as well as a delivery mechanism to benefit human metabolism 
[58].  In addition, Gao and his research group used the heat-self-assembled monolayer 
(HSAM) technique to modify the surface of 4N-Mg biomaterials.  This group conducted 
in vivo studies in which the treated and untreated magnesium materials were implanted 
into the thighbone of white rabbits to induce bone growth.  They found that the modified 
surfaces were beneficial in reducing the rate of corrosion and that corroded magnesium 
content in the blood remained within a normal range [50].     
2.3 Drug Delivery 
Drug delivery is the idea of administering pharmaceuticals to patients needing 
medical treatment in specified dosages.  There are several methods in which drugs have 
been delivered such as orally (through the mouth), topical (through the skin), 
transmucosal (through the nose), inhalation, and injection.  These methods encompass the 
ability to delivery various types of drugs and biological compounds as vaccines, proteins, 
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and other therapeutic systems.  Over the past few decades localized, or targeted delivery 
has become a favorable drug delivery method in that it limits toxicity to the human body 
by only treating the infected site [59].  This type of drug delivery system (DDS) also 
increases bioavailability of drugs [59].   
An earlier inception of localized drug delivery involved the use of drug-eluting 
nanoparticles for the treatment of restenosis.  Insertion of the nanoparticles was 
administered through a catheter apparatus.  Researchers investigated the effect of two 
different agents, dexamethasone and an aminochromone antriproliferative agent, on 
restenois in a rat carotid and porcine coronary model [60-61].  The results showed 
promising signs towards the inhibition of restenosis.  Furthermore, herparin anti-
coagulation drugs were incorporated into the nanoparticles for testing in pig coronary 
arteries for the reduction of platelet deposits and desirable results were achieved [62].  
The findings proved to be even more promising as it was observed that the nanosized 
particles could be dissolved into the arterial walls without damage to the treated site.   
Another study integrated the use of a rat model to deliver the growth factors IGF-I 
and TGF-B1 from a biodegradable matrix previously coated onto a titanium plate to treat 
the instability of long bone fractures [63].  Biomechanical testing was incorporated to 
determine if the growth factors effectively enhanced the healing process.  The results 
showed that complete healing of the fracture had not taken place 42 day after surgical 
implantation, however biomechanical strength was restored with two days of surgery.  
The results obtained from the coated group were significant compared to the controlled 
(uncoated) group [63].   
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2.4 Temporal Release 
Recent studies have introduced complex biphasic/triphasic and tetra-layered 
systems when a series of treatments are required over an extended period of time.  
Careful consideration of controllable factors such as polymer type, layer thickness, 
drug/agent use, and spatial distribution can result in distinctly, defined temporal release 
patterns.  Okuda et al. were able to develop tetra-layered nanofibrous meshes for in vivo 
testing to obtain timed-programmed release patterns [64].  Timed release was achieved 
by setting the parameters for fiber diameter, mesh layer thickness, polymer concentration, 
and the use of a barrier mesh with controlled thickness. Each layer was fabricated using 
electrospinning technique and a polymer solution doped with two different types of dyes 
to simulate the release of pharmaceutical compounds [64].   
Li et al.  present a method for achieving well-defined spatial and temporal release 
profiles for a drug-eluting MEMS device loaded with various compounds to be released 
sequentially [65].  Fabrication of the MEMS devices requires the use of an etching 
process and a silicon substrate to etch strategically placed, well containing reagents.  The 
wells were covered with a gold membrane expected to corrode based on electrochemical 
principles [65].  In the article titled “Modeling and Simulation of drug release from 
Multi-layered Biodegradable Polymer Microstructure in Three Dimensions,” cellular 
automa 3D modeling software was used to describe the dynamic behavior of multi-
layered polymer structures with uniform and nonuniform chambers [66].  The article 
presents a novel method for modeling drug delivery microstructures.  Polyanhydride was 
employed to create structures with various micro chamber shapes capable of 
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encapsulating a variety of different agents.  The structures were stacked using glue to 
create a single multi-layered structure.  The outer boundary was expected to degrade over 
time to promote sustained release [66].  A Monte Carlo based two dimensional model 
developed in the late 90’s has been able to predict prolonged release rates of encapsulated 
drugs; however, the authors determined that a three dimensional model was needed for 
more valid characterization.  The 3-D model was compared to that of the 2-D model 
using the same suggested parameters and findings were analogous.  The authors then 
optimized the parameters and formulated a hypothesis that would test the models 
performance on two different types of multi-layered systems [66].  Results showed that 
cellular automa could be used as an accurate predicting model to characterize release 
behaviors.   
2.5 Current Coating Technologies 
The coating technique proposed for surface modification and/or functionalization 
of metallic surfaces is one that is unique to a specific application.  In some cases it may 
be necessary to perform two or more different methods successively to achieve the 
desired results.  This section presents a few of the widely used methods for coating 
metallic surfaces along with their advantages and disadvantages.  Desirable 
characteristics for application of coating biological agents are also highlighted.   
2.5.1 Electrospinning 
The electrospinning process uses an applied voltage as its main source.  The 
equipment setup can either be one that is vertically or horizontally mounted [39].  
Electrospinning requires that the coating solution be loaded into a spinneret apparatus 
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where a high voltage is applied. Following the application of the voltage, the nozzle 
portion of the spinneret is subject to a whipping motion and a continuous jet is ejected 
(Figure 2.1).  The collector, or substrate, having an opposite charge is placed opposite of 
the nozzle capillary where the coating material is deposited and the thin film is formed 
[39].  
 
Figure 2.1 Schematic of the electrospinning process [43]  
The process parameters having a profound effect on such measures as fiber 
diameter, pore size, film porosity, and film thickness include: electric potential; flow rate; 
concentration of the coating material; target motion; and the distance between the 
spinneret and the target substrate.   
The process offers a number of advantages making it an ideal process for 
depositing bio thin films.  For instance, the process provides a high surface-to-volume 
ratio, good tensile strength and the use of a wide variety of coating materials.  It does not 
involve the use of heat and so it is ideal for the deposition of biological agents.  Also, 
tunable mechanical and degradations properties can be achieved.  Limitations of this 
process are subjective depending on thin film application [39].   
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2.5.2 Dip-Coating 
The dip coating process can accommodate flat or cylindrical substrates.  The 
substrate is submerged into the coating solution.  It is during this step that deposition 
takes place.  Withdrawal occurs at a constant speed and this is what determines the thin 
film thickness (Figure 2.2).  For instance, the faster the withdrawal speed, the thicker the 
thin film layer [40].  Any excess liquid is drained from the surface and the solvent begins 
to evaporate.  This process is repeated for each additional layer that is desired.   
 
Figure 2.2 Schematic of dip-coating process  
The goal throughout the deposition process is to obtain a uniform coating 
thickness with desirable film thickness and surface characteristics tailored to a specific 
application.  The tunable process parameters include the withdrawal speed, gravitational 
acceleration, rate of solvent evaporation, number of dipping cycles, dwell time, and fluid 
properties.   
Like many other thin film fabrication techniques, this process also has its 
advantages and disadvantages.  For instance, dip coating is more suitable for coating 
substrates with complex shapes and undercuts.  The production rate is extremely high as 
24  
multiple collectors can be processed at a single time.  Contrarily, coatings cannot be 
spatially controlled and the changeover time is extended making the process one that is 
inflexible for coating layers of various materials.   
2.5.3 Layer-by-Layer (Self-Assembly) 
A newer and more controllable thin film fabrication technique is layer-by-layer 
deposition.  This process involves the growth of thin films by depositing alternating 
layers of positively and negatively charged layers with a washing procedure in between.  
The bonding of the two charged layers is termed as a bilayer.  Deposition of each layer is 
usually performed by a more simplified deposition technique (e.g. dip coat or spray) [43].  
Measures of the film thickness, roughness, and porosity are usually a function of pH, 
ionic strength, and polyelectrolyte concentration (Figure 2.3).   
Due to the compositions of ionic bonding layers, one might be able to insinuate 
that a great advantage of this coating process is the fine control of drug loading and layer 
thickness.  With this process atomic monolayers of the coating materials are achievable.  
Concurrently, a wide variety of coating materials from biological agents to metallics can 
be deposited onto complex geometries.  This process does, however, pose several 
limitations in that an extra washing step required is due to excess film build up, also 
implicating a high volume of wasted material.  In addition, it was mentioned that further 
studies must be conducted to study the reaction between the charged coating materials 
and blood containing ions and polyelectrolytes in proteins [44].   
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Figure 2.3 Schematic of layer-by-layer assembly process [45]  
2.5.4 Sputter Deposition 
 Sputter deposition is a physical vapor deposition process in which a discharge of 
sputter gas, usually argon, is directed at a target containing the coating material [35].  The 
reaction between the gas (or ions) and the target materials brings about a sputtering 
reaction, which initiates the transport of atoms from the target to the substrate (Figure 
2.4).  The sputtered atoms are condensed on the substrate resulting in a thin film coating.   
 A great advantage to the application of depositing biomaterials is that this process 
does not require the use of heat, which could possibly alter the biological properties of 
the substrate.  In contrast, the bombardment of the ions may introduce impurities to the 
collector, or substrate, thus resulting in its premature degradation.  Use of this technique 
also provides the enhancement of adhesion to surface and easy control of film thickness.  
Nevertheless, the transportation of atoms is non-directional so consequently they may be 
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deposited on any surface within the vacuum chamber [35].  This can result is elevated 
amounts of waste.   
 
Figure 2.4 Schematic of electron sputtering process [46]  
2.5.5 Spin Coating 
Spin coating techniques have been used to apply thin films with less than 10 
nanometer thicknesses.  The procedure involves discharge of the bulk coating material 
from a nozzle onto the substrate, previously loaded onto a rotational tool.  The loaded 
substrate containing the coating material is then subjected to high centrifugal forces 
causing the fluid to be directed to its edges [41].  During the rotation process the solvent 
begins to evaporate resulting in a thin film coating (Figure 2.5).   
Spinning is a rapid process and the variables required to adjust the coating 
thickness is limited [41].  The primary process parameters include spin speed, viscosity 
of the coating solution, and spin time.  The use of this process, however, is limited in that 
it can only coat flat surfaces one substrate at a time resulting in a low production rate.  
Literature also suggests that after completion of deposition only two to five percent of the 
loaded coating solution remains on the substrate.  It seems, however, that the greatest 
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drawback is low repeatability and difficulty to maintain a uniform film despite 
consistency of the processing parameters.  This issue results in a number of unusual 
deformities that may be undesirable for certain applications.   
 
Figure 2.5 Schematic of spin coating process [47]  
2.5.6 Electro-Spraying 
 Electro-spraying deposition is another apparatus that employs the use of 
electricity to coat thin films.  The electrostatic forces applied to a continuous stream of 
the coating materials aids in the deposition process [36].  During this process, the liquid 
at the capillary becomes unstable to the point were it can no longer hold the charge and 
disperses into a cloud of highly charged particles (Figure 2.6).   
The process parameters having a profound effect on such output measures as film 
thickness, morphology, uniformity, and porosity include the following: growth rate, 
solvent evaporation rate, concentration, spray temperature, and deposition time.  This 
process, however, is extremely sensitive to the physical properties of the fluid and is 
limited to the use of solutions with low conductivity.  Advantages of the electro-spraying 
techniques are that it does not cause damage to the deposited biomaterials.  Also, high 
definition efficiency can be achieved (about 80%) [36-38].   
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Figure 2.6 Schematic of electro-spraying process [48]  
2.5.7 Coating Processes for Drug-Eluting Stents 
Careful consideration is required when determining the appropriate technique to 
be used for the fabrication of biological materials and thin films.  Processing that 
involves the altering of biological agents and/or their characteristics such as those that 
require the excessive use of heat or elevated pH or acidity levels should be avoided.  
When coating surfaces of drug eluting stents the drug containing solution should not be 
subjected to processes in which excessive heat or inappropriate pH levels would alter the 
performance characteristics of the device in vivo.   
Researchers at the National Cardiovascular Center Research Institute developed a 
multi-drug-eluting stent with micropores to reduce neointimal hyperplasia and minimize 
coagulation of blood platelets at the implant site.  The dip coat method was used to 
deposit a layer of segmented polyurethane (SPU) onto the inner and outer surfaces of a 
Palmaz-Schatz stent manufactured by Johnson and Johnson.  A excimer laser apparatus 
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was used for micropore fabrication and then again to ensure immobilization of the 
heparin coating (inner surface) and FK506 immunosuppressant (outer surface) coatings 
that were applied [67]. 
The coating method that was chosen aided in the prevention of plaque build-up 
within the struts of the stent, limiting thromboresistance.  The technique resolved the 
issue of the undesired structure of the luminal surface resulting in the flat surface needed 
for experimental success.  The irradiation process used for the immobilization process did 
not pose any threat to the functionality of the chosen biological agents.   In vivo results 
showed that the multi-drug coating did reduce neointimal hyperplasia and thrombosis 
[67].   
Another study claims the development of a novel biodegradable polymeric 
matrix-coated cardiovascular stent for controlled drug delivery through the use of an 
individualized drug-eluting stent system to abrogate restenosis (ISAR).  The authors here 
use a modified air suspension coating technique in which the wire mesh-like stent is 
suspended vertically between two hooks that are linked to the coating device.  The 
coating solution reaches the 0.2mm diameter nozzle while under gravitational influence 
and is eventually ejected from the capillary and subjected to a pressure drop atomizing 
the liquid into fine droplets.  Multiple layers (4) of coating solutions were collected on 
the rotating stent [68]. 
 It was observed that the coated stent in this study maintained a standard uniform 
coating free from impurities following the successful optimization of parameters such as 
gas pressure, flow rate of the solution, and distance between the nozzle and stent.  
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Mechanical properties of the coating were also tested at stent site and subjected to the 
maximum permissible stress.  The results of SEM imaging and the findings of film 
stability confirmed complete adhesion of the film.  Finally, processing of the coating 
materials through the use of gravitational forces and air pressure did not result in the 
alteration of either the biological components or substrate [68].   
 In a research study published by the American Heart Association, an on-site 
coating apparatus is used to apply pharmaceuticals for the direct use of drug eluting 
stents.  The process maintains sterility throughout the duration of the application period.  
The drug-eluting stent fabrication design allows for individual doses of a specified drug 
in a drug reservoir to be connected to a disposable stent cartridge under sterile conditions.  
The stent, mounted onto a balloon catheter is positioned inside of the disposable cartridge 
and is ultimately motioned horizontally through a ring containing three nozzles.  Upon 
application of the coating solution via spray coating mechanism, the stent is dried by 
sterilized air pressure and is removed for immediate use [69].   
 A process such as this was necessary to ensure that materials are free from 
contamination.  Given that the deposited solutions are bare drugs, appropriate precautions 
were taken to ensure that the functionality of the drugs is not disturbed.  The coated drug-
eluting stents were immediately used for inhibition of neointima, or accelerated growth of 
unwanted cells.   
The recent application of this method was carried out for the fabrication 
rapamycin-eluting stents [70].  The systematic release of probucal was also reviewed.  
This non-polymeric coating technique was sought as a method to deliver drugs in a way 
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that does not introduce unnecessary cardiac events into the healing process.  To assess the 
effectiveness and safety of these newly developed stent coating techniques, rapamycin 
and polymer coated stents as well as a control (bare metal stents) were placed in a porcine 
model where the effects of fibrin deposition was closely monitored [70].  Results showed 
that fibrin deposition was significantly higher in biodegradable polymer-based stents.   
2.6 Uses of Ink-jet Printing Technologies  
The use of inkjet printing technologies for the deposition of biological materials is 
becoming more relevant for applications in biomanufacturing.  The non-contact printing 
technique has been used for the fabrication of solid and multilayered microspheres, 
deposition of biopolymeric materials for uses in tissue engineering, and bioMEMS and 
microfluidic applications [71].  Inkjet printing, also referred to as a direct-write process, 
offers several advantages in the deposition of biological agents such and DNA, proteins, 
and growth factors for tissue engineering applications.  A primary advantage is that 
during the deposition process, the coating materials are not subjected to elevated 
temperatures that could potentially alter both the biological and fluidic properties [71].  
Other advantages of this technique are its ability to produce highly uniform microdroplets 
as well as a precise deposition tool to fabricate very small and complex structures.  A full 
list of advantages can be found in Table 2.1. 
 In an article released from MicroFab Technologies, Cooley et al. presents inkjet 
printing as a suitable technique for manufacturing biological micro-electromechanical 
systems (bioMEMS) [72].  The current technique for the fabrication of these devices 
consists of photolithographic process that requires exposure and/or etching of 
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biomaterials to create a pattern or coating. The etching process lacks control, which 
affects the thickness of the applied coatings. The direct-write technique is a safe 
procedure that does not introduce harmful chemicals.  It is a three-dimensional printing 
process that allows for easy manipulation and achievement of uniform coating 
thicknesses [72].    
Table 2.1 Advantages of Direct-write inkjet technique 
Advantages of Direct-Write Inkjet Printing 
1. Non-contact, reduced cross-contamination of substrates 
2. No thermal influence 
3. Precise and accurate printing 
4. Prints a variety of materials and biomaterials on a variety of substrates 
5. Fast Process 
6. Low start-up cost 
7. Data-driven and safe process 
8. No chemical waste  
 
 The inkjet printing process may be achieved using one of three different methods: 
thermal, continuous, or piezoelectric drop-on-demand.  For reasons mentioned above, the 
use of the first two methods have been discouraged for printing biological agents onto 
small, complicated structures.   
 In a recent study, also conducted in conjunction with MicroFab Technologies, 
Inc., a standard JetLab system was used to fabricate PLGA microspheres, which had been 
loaded with paclitaxel drug and thin films of fenofibrate for stent coating applications. 
The materials selected were required to meet four specific criteria: 1) the ability of the 
material to degrade after performing its drug delivery function 2) the ability to sustain 
cell viability 3) the ability to sustain proper cell functioning and 4) the ability to be jetted 
at high concentrations for extended time periods [73].  
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Drug release and bioactivity of the drug containing microspheres and thin films 
were observed using UV spectroscopy and MTT assay respectively.  The results obtained 
showed that the drug containing microspheres were able to sustain release of the 
paclitaxel drug for at lease 50 days with 80% of the loaded drug being released.  The 
results of the MTT assay proved that the inkjet printing techniques did not alter the 
functional properties of the drug [73].  Attesting to the claims of high speed and accurate 
deposition, release profiles from the coated stents demonstrated that this technique could 
be used to improve drug-loading efficiency as compared to other coating techniques.   
A more recent study was conducted to revisit the use of commercial inkjet 
printers and ink cartridges, which have been modified for bioprinting applications [74].  
Khan et al.  sought to prove that when using a modified inkjet printer, the short period of 
time in which bio-inks containing proteins are subject to elevated temperatures are 
negligible and, in fact, enzymatic activity was present after printing[74].   
 The need for a more suitable deposition technique for stent coating applications is 
desired that can achieve high drug loading efficiency through accurate and localized 
printing methods and maintain extended drug release periods.  A review of current 
deposition methods for biofunctional surface modification applications has been 
presented, each with their parameters, benefits, and limitations.  It has been shown that, 
while each technique has its list of advantages, they are relevant only for certain 
applications.  The use of other more conventional deposition methods has been 
discouraged whether it be for issue with substrate contamination, lack of control during 
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the deposition process, or the possibility of decreasing bioactivity upon being subjected 
to heat or some harsh chemical.   
Many techniques have been used to coat drug-eluting cardiovascular stents for 
drug delivery and a combination of techniques have been used to grow multilayer thin 
films.  However, none have employed the use of piezoelectric direct-write systems to 
develop polymeric coatings for corrosion retardation of magnesium alloys and drug 
release of antiproliferative cancer drugs.   
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CHAPTER 3  
METHODOLOGY 
3.1 Overview 
 Direct-write printing is a novel method that is currently being considered for the 
development of targeted and precise polymer coatings for a vast number of biomedical 
applications.  More specifically, these coatings can serve as protective barriers when 
applied to the surface of an implant device and/or be used as a mechanism for the 
delivery of anti-proliferative drugs via a coated stent model system.  The device or stent 
model system consists of the substrate, or biomedical device, in which the coating is 
applied, and the coating itself.  The nature of the coating can take a variety of forms with 
the ultimate goal of achieving a specific release profile.   
 In the sections to come, a system of experiments is described that will provide an 
understanding of the factors which have a profound impact on drug release profiles from 
biodegradable thin films fabricated using direct-write printing technologies.  A second set 
of experiments will describe the effectiveness of polymeric coatings, applied using this 
same novel technique, for the retardation of magnesium corrosion.  Details of the 
experimental design and process description will be provided followed by a mention of 
the possible challenges.   
3.2 General Approach  
 Titanium and its alloys are among the list of metallic biomaterials used to 
manufacture surgical implant devices (i.e. stents, orthopedic implants).  Other noted 
metals include stainless steel and cobalt-based alloys.  Metallics as biomaterials are ideal 
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due to their ability to resist the fatigue, wear, and fracture sustained from the daily forces 
present in the body.  The inert presence of these materials also makes them ideal for use 
within the body, as they do not present any obvious adverse effects when implanted into 
the host site.  Many of the cardiovascular stents on the market are made using stainless 
steel; however, this dissertation will employ the use of polymer-coated titanium alloy 
substrates as a model system to simulate the behavior of drug-eluting stents because of 
their strength and biocompatibility in biological environments. 
 Despite the excellent strength and corrosion resistance properties of titanium for 
the manufacture of biomedical devices, there exist some limitations.  The most important 
is that the surface oxidized layer, which forms after the natural reaction between the 
titanium atoms and the oxygen atoms present in body fluids, can also be disrupted by the 
metallic ions.  Extensive research has been conducted that suggest different ways in 
which surface modification of titanium can enhance its biocompatibility.  Also, since the 
introduction of synthetic and biodegradable polymers for biomedical uses in the early 
1900’s, they have been successfully applied in a number of ways to advance the 
properties of metallic biomaterials.   
 Hwal Suh, suggests three classifications of polymeric biomaterials in an article 
titled, “Recent Advances in Biomaterials” [75]. The use of biodegradable polymers to 
coat metallic materials not only add flexibility to the metal but also provides the 
additional benefit of mimicking the functionality of the surrounding tissues present at the 
host site.  As a result the implanted material is able to remain at the implant site for 
extended periods and not pose any immunological threat.  Biodegradable polymers have 
37  
the ability to absorb within the body, and in some cases, regenerate lost tissue and or 
cells.   
 An added dimension to the use of biodegradable polymers for coating medical 
devices is their ability to sustain and transport medicinal drugs for prolonged drug 
release.  This is possible due to the natural characteristics associated with a specific 
polymer type.  The degradation properties of a given polymer type is one factor that has a 
significant effect on the time in which it is capable of sustaining drug release.  A second 
factor is the physiological environment in which the degradation process takes place.  
Some commonly used biodegradable polymers for drug delivery include poly-(lactic-co-
glycolic acid) (PLGA) [76-78], polycaprolactone (PCL) [77,78], and poly(ether urethane) 
urea (PEUU) [78].   
 The listed polymeric biomaterials all possess exceptional biocompatible and 
biodegradable properties.  As such, they have been approved for use in the human body 
specifically for drug delivery applications.  However, research is currently being 
conducted to improve its biostability.  The degradation rates of these polymers have the 
ability to be manipulated such that a desirable rate of release may be achieved [78].  For 
instance, PLGA, which consist of the natural monomers lactic and glycolic acid, can be 
manufactured in such a way that the ratio of lactic acid to glycolic acid is 75:25 resulting 
in a faster degradation rate.  Several other advantages to the use of these polymers 
support the decision for its use.   
 Drug release rates not only depend on the polymer type, but also the 
pharmaceutical agent and a specified dosage.  The types of drugs chosen to deliver drugs 
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from cardiovascular stents are numerous, yet they are dependent on the application.  For 
instance, if the main purpose is to prevent coagulation of blood platelets or increase blood 
compatibility of the device then the choice of drug may be Heparin.  Chemotherapeutic 
drugs have also been used to treat late stage lung cancer patients [79]. A common drug 
that is used to inhibit the increased growth or proliferation of unwanted cells around the 
stent device is Paclitaxel, also referred to as Taxol [80].   
 Paclitaxel is an antimicrotubule agent that is used to treat an array of cancers (e.g. 
breast cancer, lung cancer, ovarian cancer).  This drug is usually used after other 
treatments have been explored and have resulted in failure.  Uses of this drug in excess 
can lead to depletion of the white blood cells needed to fight infection thus resulting in 
fatality.  Ideally, this drug would be delivered in small amounts over extended periods of 
time, making it the perfect candidate for testing release from biodegradable polymers 
[80].   
 The use of bioinert metallics can eventually lead to foreign body reaction 
following implantation due to the body’s inability to recognize the material as one that 
compliments normal physiological processes.  Thus, magnesium and its alloys have been 
identified as a lightweight metallic biomaterial that can withstand the daily forces 
imposed by natural body function.  It is also the fourth most abundant element found in 
the human body making it essential for many of the physiological processes.  Magnesium 
is an ideal candidate for surgical implant materials because of its ability degrade after 
performing its intended purpose without posing any toxic effect to the body.   
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 Although, magnesium has been identified as an ideal candidate for surgical 
implants such as cardiovascular stents, the issue of its fast corrosion rate still remains.  
Thus, in a second study we propose that the application of biodegradable polymeric thin 
films can be used as a method for retardation of the corrosion process.   
 The deposition process for loading the drug containing polymer matrix onto the 
titanium substrate is one that should also be carefully chosen, particularly for coating 
complex structures such as stents.  A description of the commonly used deposition 
processes for surface coating and modification is found in preceding chapters.   
 Direct-write inkjet printing offers several advantages to the process of coating 
metallic devices such as stents for biomedical applications.  One main advantage is the 
ability to print local and precise patterns onto three-dimensional structures.  With stent 
coating the ability to print precise patterns is ideal because of its complex, helical, mesh-
like design.  This technique also prevents webbing of the coating materials, which has 
been known to alter the stents functionality.  Direct-write printing techniques also permit 
biological agents such as drugs and proteins to be deposited without altering their 
physical and chemical compositions.   
 The present research uses the direct-write inkjet printing technique to 1) deposit 
biodegradable polymer thin films, laced with the antiproliferative paclitaxel drug, to coat 
bioinert titanium substrates and 2) apply polymeric thin films to a magnesium alloy as a 
protective barrier for corrosion retardation.    
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3.3 Governing Facilities and Equipment 
 This research is conducted in conjunction with the National Science Foundation 
Engineering Research Center (ERC) located in the Interdisciplinary Research Center at 
North Carolina Agricultural and Technical State University.  The present study is only a 
small segment of the ongoing research within the ERC which consists of three 
Engineered Systems: (I) Craniofacial and Orthopedic Applications, (II) Cardiovascular 
and Thoracic Devices and, (III) Responsive Biosensors and Neural Applications.  
Research at the center relies on four enabling technologies: biodegradable metals, 
biofunctional surface modification, sensing and controlled degradation and, controlled 
release.  This dissertation will focus on the ES-II component driven by biofunctional 
surface modification and controlled release technologies.   
3.4 Fundamental Challenges 
 Several challenges have been noted, however they are not expected to have a 
significant impact on the validity of this research.  The first challenge is that, although we 
are using planar titanium substrates as the model stent (which are actually three 
dimensional), the direct-write system used in this research is not actually capable of 
printing on these types of structures.  A second challenge is that the consistency between 
batches of biological agents and polymers could see small variations in their physical 
properties, which could have an effect on the outcome of the experimental results.  These 
variations can be taken into account in the analysis portion of the research to ensure that 
this research effort remains valid.   
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 Pertaining to the direct-write inkjet printing technique that will be used to coat the 
titanium substrate, there are several challenges that may be encountered.  For instance, 
this technique is limited in the fluids that can be jetted.  Fluids having non-Newtonian 
properties, which are highly viscous, may not be appropriate for deposition by this 
technique.  Thus, drug loaded carriers or thin films may not be loaded with a realistic 
dosage of drugs needed for treatment.  Also, this process is sensitive to the properties of 
the fluids being jetted making it difficult to obtain the optimal jetting parameters for a 
given fluid concentration.  As a result, the jetting optimization process can be time 
consuming making it sometimes infeasible to obtain a large number of samples as might 
be suggested from conducting a statistical power analysis.  Moreover, the optimal jetting 
parameters obtained for a given fluid varied from one user or jetting session to the next.  
Though not able to be completely eliminated, these challenges were minimized by 
designing a protocol for reaching optimal jetting parameters as well as equipment training 
sessions.    
3.5 Methods and Materials 
 This section will provide a description of the processes and factors, which are 
expected to have a significant effect on the output parameters.  The output parameters are 
also stated with a description of each to follow.     
3.5.1 Direct-write Equipment and Jetting Optimization Process 
 The deposition technique chosen for this research is a modified inkjet printing 
technique designed by MicroFab Technologies Drop-On-Demand Test Stand inkjet 
system (MicroFab Technologies, inc., Plano TX).  This system consists of a pneumatic 
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controller, a MicroFab JetDrive III external waveform generator with heat source, 
JetServer software with waveform amplifier, horizontal- and vertical-plane optics system 
and a piezoelectric nozzle tip with a 50-micron orifice diameter [48].  The schematic of 
the MicroFab test stand is pictured in Figure 3.1.  
 
(a) 
 
(b) 
Figure 3.1  (a) Depiction of MicroFab JetLab 4 inkjet printing machine  (b) nozzle 
printing apparatus and motion panel 
 
Direct-write inkjet printing can be accomplished using one of two different inkjet 
technologies, Continuous (CIJ) and Drop-on-Demand (DOD) inkjet printing.  More 
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suitable for this research is the DOD (or direct-write) technology.  This method requires 
electromechanical pulses (or an applied voltage) over a piezoelectric material that causes 
the material to deform.  The deformation of this material causes an increased pressure 
within the nozzle after which a single droplet is ejected [48].   
After the droplet is ejected, there is an obvious reduction of fluid volume within 
the solution-containing reservoir, thus the solution must be replaced.  As the piezoelectric 
crystal returns back to its resting state, a negative pressure forces the replacement of the 
ejected fluid [48].  A list of the input parameters required to characterize the above 
described process is in Table 3.1. 
   Table 3.1 List of piezoelectric Direct-write parameters 
Piezoelectric Direct-Write Process Parameters 
1. Frequency 
2. Jetting Voltage 
3. Waveform (driving signal) 
4. Print head Design 
5. Jetting Fluid Properties 
 
It is desired to optimize the jetting process to achieve a steady stream of 
uniformly shaped droplets for the deposition of thin film coatings onto prepared titanium 
substrates.  The parameters, which influence this optimization process, include: pulse 
waveform, print head design, and jetting fluid properties (Figure 3.2).  A description of 
the print head design has been discussed previously.  It is designed to include a nozzle 
orifice as low as 10 micrometers in diameter where it is expected that the variations of the 
droplet size (diameter) distribution from the orifice diameter may be neglected.   
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Figure 3.2 Direct-write process parameter relationship 
 
The pulse waveform requires its own set of parameters that can be optimized for 
the manipulation of drop size and speed, jetting sustainability, drop placement and drop 
uniformity. The waveform parameters include the frequency, positive/negative jetting 
voltage, rise time, dwell time, fall time, and final rise time denoted by f, +V/-V, TR, TD, 
TF, and TFR, respectively.  Where the jetting voltage is the optimal voltage (+V) applied 
causing deformation of the piezoelectric material. –V is usually set at 0, setting the 
voltage back to 0 and returning the material back to its initial resting state [81].   
The rise and fall times with respect to the characterization of the pulse waveform 
are the time for the driving signal to reach the optimal amplitude (voltage) and the time 
for which it takes to decrease the voltage back to its original state.  The dwell time that 
the optimal voltage is applied to the piezo material and the frequency refers to the 
number of drops jetted over a given time span.  Figures 3.3 (a) and (b) below depicts the 
resulting waveform for piezoelectric direct-write processes and the MicroFab JetServer 
interface used to vary these parameters respectively.   
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(a) 
 
(b) 
Figure 3.3 (a) Depiction of JetLab interface (b) pulse waveform formation 
 
Much research has been conducted on the manipulation of the waveform shape 
and parameters to determine their effects on the jetting process.  Such a parameter that 
contributes greatly to the success of the jetting process is jetting stability.  The jetting 
stability is greatly affected by the retraction of the meniscus (fluid surface at the nozzle 
tip), which is directly related to the reservoir pressure resulting from TF.  Polymer 
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buildup at the nozzle tip negatively affects the success of the jetting process.  In literature 
this is referred to as puddling and is directly related to the frequency of droplet 
accumulation.   
A final parameter having a significant effect on the jetting process is the jetting 
fluid chosen and its associated fluid properties [82].  The fluid properties significantly 
affects the jettability of a substance, which is the fluid’s ability to maintain a jet stream of 
droplets for an extended period of time (e.g. two to three hours).  Jettable fluids can be 
broken down into two categories: Newtonian and Non-Newtonian fluids [82].  This 
research deals with polymeric solutions, which display Non-Newtonian properties, that 
is, fluids with high viscosity, density, and surface tension values.   
The manipulation of fluid properties can be obtained by varying fluid 
concentration (in this case, polymer concentration) given a solid polymer percentage 
(weight, %) and solvent (volume, mL) to obtain a weight/volume solution.  More 
specifically, the concentration of a given polymer such as poly(lactic-co-glycolic acid) 
(PLGA) used in our experiments, can be altered by adjusting its ratio of lactic and 
glycolic acid to obtain a higher concentration of solution thus resulting in a higher 
viscosity.  The effects of the fluid properties directly relate to tail break-off of the jetting 
solution. Also, a more viscous solution will have a longer tail (break-off period), which 
will slow the drop speed.   
 Residual vibrations may occur even after a single drop has been ejected and could 
influence the nature in which the resulting drops are ejected.  Robustness against 
disturbance deals with the optimal parameter settings and system abilities in dealing with 
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such disturbances as dust and air bubbles that could stop the jetting process.  Lastly, 
aging of the piezo material could have a profound effect on the optimal achievable jetting 
process parameters. There are many other operational issues that could limit the 
optimality of the direct-write printing process, however, these issues were controlled to 
the best extent possible. 
3.5.2 Characterization of Coating Morphology and Thickness 
Surface morphologies were characterized using optical and scanning electron 
microscopy.  The use of this technique allowed for monitoring any changes regarding the 
coating surface, not only before and after optimal release has occurred, but also to track 
any possible changes in thickness during sample collection periods.  This is due to the 
non-destructive nature of the imaging process.  For further characterization, SEM 
imaging may be used before and after sample testing periods but only for general 
characteristics across groups of samples at the same stage in the testing process.  This is 
attributed to the destructive nature of SEM sample processing. The film thicknesses of 
the drug loaded polymeric coatings were evaluated by using both scanning electron 
microscopy and optical profilometer, respectively where the polymer film was cut to 
reveal the cross-section areas and thickness profiles.  The SEM technique was also used 
for qualitative characterization of surface interaction between blood platelets and drug 
loaded polymer coatings.  Images resulting from this technique were also used to quantify 
adhesion of the platelets to the surface. 
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3.5.3 Characterization of Drug Release 
Release kinetics for the characterization of release profiles were measured using 
Ultra-Violet Spectrophotometry techniques.  This technique is generally used to detect 
traces of a given substance within a sample by transmitting a source of light through its 
contents to measure its absorbance.  The absorbance is measured over a given wavelength 
where a maximum absorbance is said to exist.  For example, literature states that the 
wavelength for which the maximum absorbance reading for Paclitaxel may be obtained is 
somewhere in the realm of 227 nm.  This wavelength value for achieving the optimal 
absorbance readings for the samples were validated using a Shimadzu UV-2450 
Spectrophotometer to ensure repeatability.  Performing serial dilutions on concentrated 
paclitaxel solutions and gaining absorbance readings from the UV spectrophotometer, we 
were able to develop a standard curve.  The process described allowed us to calibrate and 
compare the release values on the standard curve to determine total concentration of the 
drug, which was released.  
3.5.4 Selection of Materials  
  The placement of foreign bodies, specifically bare metal stents (BMS), within the 
human body can pose serious threats at the implant site.  Moreover, the rapid growth of 
undesirable smooth muscle cells triggered by the presence of the foreign body is found to 
be a main cause of late-stage restenosis.  The collapsing of the cardiovascular stent, due 
to excessive forces is caused by neointimal hyperplasia.  Generally cardiovascular stents 
and other surgical implant devices are manufactured using metallic materials, such as 
49  
stainless steel, nickel, and titanium, which are not recognized within the physiological 
environment.  
 This research focuses particularly on the manufacturing and design aspects of 
drug delivery systems (DDS’s).  Thus, an actual cardiovascular stent will not be used.  A 
bare titanium substrate will be used as a substitute.  For the characterization of the 
controlled release coatings, 10x10 mm coupons were used primarily to scale up the drug 
concentration so that absorbance detection was possible.  For biological testing, the 
titanium substrates used were round having an approximate diameter of 6 mm.  The 
round shape of the substrates is necessary to conduct an MTT assay for the determination 
of cell proliferation later on in this study. 
 For the characterization of polymer coatings for corrosion inhibition, a 
magnesium alloy with the composition (Mg:90%, Zn:8.9%, Ca:0.5%, rest impurities) was 
smelted as ingots within an inert environment (argon) in our laboratory. The Mg alloy 
was used as-cast without further processing such as cold work or heat treatment. A flat 
piece (10mmx10mmx2mm) of this Mg alloy was casted into a disc-shaped epoxy resin so 
that only the top surface of the Mg alloy was exposed. This is because we are interested 
in studying the corrosion behavior of Mg alloy with different polymeric coatings on only 
the top surface without affecting the corrosion of the other sides. The sample top surface 
was then polished to eliminate the magnesium oxide layer.  
 The general expectations of a biopolymer suitable for coating cardiovascular 
stents is that 1) it must be biocompatible; 2) it must demonstrate selective permeability; 
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3) it must have the ability to biodegrade; and 4) it must demonstrate high mechanical 
strength.  A depiction of the aforementioned (Figure 3.4) and a brief description follows.   
 
 
Figure 3.4 Characteristics of biopolymer for stent coating applications 
 
Biocompatability of a polymer can be measured in a number of ways.  One 
common measurement is to count the number of plasma protein, or blood platelets, that 
accumulate at the surface of the polymer over a period of time.  If amassing is excessive 
than it can be concluded that that the polymer is biologically incompatible.  A second 
qualitative measure is excessive tissue growth at the implant site.  This leads to a 
discussion of mechanical strength.   
 In keeping perspective of the excessive tissue build up around the bare metal 
stent, the remaining requirements of a biodegradable polymer is further discussed.  The 
application of a thin film biopolymer coating displaying high mechanical strength could 
aid in maintaining the structural vigor of the of the stenting device for lengthier periods 
of time.  Alongside good mechanical strength is selective permeability.  The polymer 
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membrane should maintain some level of control over what is allowed to cross it and the 
rate at which any substance (or drug) is allowed to do so.  In a practical sense, the drug, 
paclitaxel, is expected to permeate through the polymer membrane at a controlled rate to 
slow the growth of the smooth muscle cells.  The decreased rate of cell growth due to the 
controlled release of paclitaxel along with increased mechanical strength is said to 
decrease the probability that restinosis will occur. 
 The preparation stages are expected to be one of the most vital segments of the 
series of components involved.  This is due in part to the extremely high volatility of the 
materials that will be used.   Aside from that, the dosages of paclitaxel to be embedded 
into the polymer are so small that special care must be taken in making sure that all 
materials are measured accurately in order to decrease variations of the results obtained. 
 Recall that paclitaxel has been chosen to simulate release profiles for alternative 
drug-polymer systems.  Paclitaxel (taxol) is a cancer treatment compound, which is 
derived from the bark of taxus brevifolia found in the Pacific.  Taxol is commonly used 
to treat breast, ovarian, and late stage lung cancers as well as occurrences of restenosis 
within the arterial wall.   
 Though recently there has been much controversy to the use of this drug, its use 
as an inhibitor of the rapid division of undesirable cells has proven effective for the 
treatment of rapidly growing tumors and neointimal hyperplasia.  The compounds 
effectiveness can be attributed to its ability to inhibit the breakdown process of 
microtubules, a major component of the cell division process. The molecular breakdown 
of paclitaxel is depicted in Figure 3.5 below.   
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Figure 3.5 Breakdown of a single molecule of paclitaxel 
 
 The uses of paclitaxel for the drug-loaded polymer thin film coating is desirable 
for stent coating applications mainly because it has demonstrated properties such as anit-
proliferative and anti-inflammatory on cell interaction.  Drug-eluting stents, using 
paclitaxel, are necessary to inhibit unwanted cell growth that will prevent the re-
narrowing of the arterial wall due to this growth.   
 Preceding the discussion of Taxol’s dissolution mechanism, the mention of the 
difficulties in characterizing these properties is deemed necessary.  It is important to 
understand the process by which this drug is obtained and how drug development can 
contribute to variations of its dissolution properties.  For instance, a recently reviewed 
article attributes the challenges of describing the dissolution of paclitaxel to variations 
between batches of the drug resulting from the different environmental factors of which 
the drug was subjected.  Examples of factors that influence these variations include; 
weather, soil composition, water and sun.  It is inferred that these factors could indirectly 
impact the repeatability of dosages required to treat tumor growth and, in our case, 
neointimal hyperplasia.   
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 Aside from possible variations between batches of the drug, paclitaxel has 
demonstrated low solubility within the physiological environment.  This phenomenon 
been demonstrated in vitro, via studies of dissolution after incubation in phosphate buffer 
saline (PBS) solution at 37 degrees Celsius to simulate physiological environments as 
well as in vivo in numerous rat models.  Taxol is generally mixed with harsh solvent to 
relax its dissolution.  It has been noted in recent in vitro studies characterizing the 
insolubility of paclitaxel that increased concentrations of the drug between 1% and 5% 
w/v, homogeneously dispersed in aqueous polymer solution, begin to crystallize 
following polymerization after a period of days.  This is a phenomenon that was realized 
in the preliminary studies of this research.  Figures 3.6 (a) and (b) below depict the 
spherical shape of crystallized paclitaxel by scanning electron microscopy (SEM) 
technique (courtesy of the Engineering Research Center at North Carolina A&T State 
University).  Images were taken at 800 x and 4,000 x magnification respectively.  The 
reduction of drug particle size is a good aim in future studies of taxol release towards the 
improvement of solubility.   
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(a) 
 
(b) 
Figure 3.6 (a) Precipitated taxol beads of PEUU surface 800X (b) 4,000X 
 
For each of the proposed systems variations of polymer and drug concentration, 
as well as thickness may be applied to achieve the critical viscoelastic and mechanical 
properties desired for optimal drug release.  It is important to note that the optimality of a 
given drug release profile is dependent on the application.  A list of parameters affecting 
the viscoelasticity of a given polymer solution is provided in the Table 3.2 below 
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followed by a diagram (Figure 3.7) depicting the influence of viscoelasticity in drug 
release.   
                      Table 3.2 List of viscoeleastic parameters 
Parameters of Viscoelastic Polymer Solutions 
1. Temperature 
2. Pressure 
3. Time 
4. Polymer Chemical Composition 
5. Molecular Weight 
6. Crystallinity 
7. Solvent Dilution 
8. Polymer/Mixture Composition 
 
 
Figure 3.7 Influence of viscoelastic properties on drug release 
 
The viscoelastic properties strongly influence the polymer systems ability to 
maintain structural and mechanical drug efficiency.  However, there are other factors that 
contribute the integrity of these designed systems.  Some of the most influential factors 
include particle size distribution, physical state and concentration profile of the drug with 
the polymer thin film, and dissolution and diffusion properties of the drug. An effort to 
maintain structural and functional integrity has been considered in the design of the 
proposed polymer thin film systems. 
 A review of literature regarding the dissolution and diffusion properties of taxol in 
PCL and PLGA, two other biocompatible polymeric materials, is presented.  S. Dordunoo 
et al.  characterized the release of taxol from PCL microspheres (Dordunoo et. al, 1995).  
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It was determined that crystallinity of the polymer is said to be lower with increased taxol 
loading which resulted in reduced times for degrading.  Furthermore, accumulated 
crystallized taxol particles resulted from increased drug loading (5% to 10% w/v), again, 
a phenomenon that was validated in our studies.  This is said to provide a pathway, 
initiating at the polymer surface, which could be responsible for the fast paced dissolution 
of the drug.  This is an indicator that the drug loading exceeds the capacitated efficiency 
of the polymer solution (saturation) or a lack of homogeneity of the drug-polymer 
solution.  The findings for taxol release from PLGA nanoparticles demonstrated similar 
results, with the exception that faster release rates were obtained. 
 The present study uses a biodegradable polymer, polyetherurethane urea (PEUU) 
coating, for characterizing the release of a chosen drug, namely paclitaxel for simulating 
drug release.  PEUU is chosen as a candidate polymer for testing due to its excellent 
biocompatibility and high mechanical strength. 
The use of drug-loaded polymers as thin film coatings for the purposes of 
conducting therapeutic sessions is eminent for cardiovascular stenting applications.  The 
combination of the biopolymer and curative drug work together as a drug delivery system 
(DDS) to administer treatment for ailments such as neointimal hyperplasia, the fast-pace 
growth of unwanted cells, restenosis, as well as late-stage lung cancer patients.  It is 
desired to achieve a DDS, via cardiovascular stent device, that can maintain compatibility 
within the physiological environment yet retain its ability to achieve drug release over 
extended time periods.  
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Along with PEUU, PLGA and PCL were chosen to coat alloyed magnesium 
substrates to study the controlled corrosion mechanism.  PLGA is chosen here because of 
its excellent biodegradability and biocompatibility properties.  It has already been 
approved for applications in developing therapeutic and implant devices due to the notion 
that it poses little to no toxic by-products to the body.  In fact, PLGA undergoes 
hydrolysis within the body to produce the natural monomers, lactic and glycolic acid, 
which are by-products of various metabolic pathways found in the body.   An added 
benefit of its use is that degradation rates can be manipulated by changing the monomers 
ratio (lactic: glycolic acid).  For example, PLGA 70:30 consists of 70% and 30% of lactic 
and glycolic acid respectively.  It is known that higher amounts of glycolic acid decrease 
the time for degradation.   
 The second polymer, PCL, is polyester, which degrades by hydrolysis of its ester 
linkages.  The degradation rates here are said to be much slower than that of the other 
two; however, this polymer also demonstrates excellent biodegradable and 
biocompatibility.  PCL has also been approved for uses in the human body by the FDA 
for applications such as drug delivery devices and adhesion barriers.  An added benefit is 
that PCL is less viscous as a solution compared to the others making it an ideal candidate 
for printing using our novel direct-write printing technique.  Lastly, as mentioned earlier, 
PEUU is chosen as a candidate polymer for testing due to its excellent biocompatibility 
and high mechanical strength. 
PCL as well as PLGA were not only chosen because of their excellent 
biocompatible and biodegradability, but also because they provide other advantages to 
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the development of polymer thin film layers.  For example, the FDA has approved PCL 
for barrier uses in biological components and PLGA degradation rates can be altered 
through systematic manipulation of its molar ratio. 
3.6 Controlled Release Coatings (Phase 1) 
 Controlled release coatings are fabricated to suit a variety of different 
applications.  More specifically, the controlled release of various biological agents from 
biodegradable polymer coatings to treat a vast number of physiological ailments is of 
particular interest.  The use of the Direct-Write inkjet technique as a mechanism for 
developing controlled release coatings offers a variety of advantages for coating surfaces 
containing biological and pharmaceutical reagents [48].  For instance, this technique uses 
a data-driven pressure source for deposition of material onto a given substrate, where 
other fabrication techniques use electricity, which may compromise the integrity of the 
biological substances [48].  Other techniques such as spin coating and dip coating are not 
able to accommodate the complex structures that are usually required by surgical implant 
devices.  None of the deposition techniques discussed earlier offer the ability to deposit 
target specific coatings, maintain the integrity of the deposition material, and eliminate 
cross-contamination of materials.   
 The need for a coating technique that encompasses all of the benefits mentioned 
above is necessary to develop controlled release coating where spatial requirements can 
be specified to develop coatings with specified porosity and degradation features.  In this 
research, the intent was achieve a variety of drug release profiles that could be tailored to 
support the needs of a given drug delivery application.  Here, the drug concentration and 
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layers of coating material were varied to assess coating specifications resulting in a 
steady state release throughout its intended time of function.  This result would be 
desirable for ailments requiring extended therapeutic sessions such as neointimal 
hyperplasia, using an anti proliferative such as Paclitaxel, following placement of a 
cardiovascular stent device [6].  Coatings having a more profound initial burst phase were 
also attempted.  These coatings would be more suitable for applications such as 
antimicrobial and/or antifibrotic therapy were the majority of the reagent is required in 
the initial stages of treatment to treat infection at the implant site and promote healthy 
wound healing [83-84]. 
3.6.1 Materials Synthesis  
 Traditionally, cardiovascular stents are fabricated from stainless steel (SS) or 
titanium (Ti) materials. In this research, a metallic substrate (Titanium) was used to 
mimic the surface properties of the Ti stent. A 10mm x10mm Ti sheet was deposited with 
drug loaded polymeric formulation to evaluate the drug release kinetics and coating 
morphology as described herein.  
Biodegradable polyester urethane urea (PEUU) was synthesized at a proprietary 
source (University of Pittsburgh) and obtained for the experiments. The PEUU was 
dissolved in hexiflouroisopropanol (HFIP) solvent (Sigma Aldrich) and shaken 
vigorously until homogenous polymer solutions of 1%, 1.5%, and 2% w/v were obtained. 
These polymer concentrations were chosen based on the rheological properties of fluids 
to ensure that they were “jettable” from the direct-write inkjet system. Paclitaxel (Taxol) 
drug (LC Laboratories) was added at 5% and 10% w/w of the respective PEUU 
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concentrations within the biopolymer solutions. The drug paclitaxel is an inhibitor of the 
rapid division of malignant cells and has been proven effective for the treatment of 
rapidly growing tumors (cancer cells) and neointimal hyperplasia. Prolonged release of 
the drug from multilayered thin film coatings on cardiovascular stents is proven to be 
beneficial against this malady.  
3.6.2 Sample Fabrication 
Biopolymer solutions with varying concentrations of PEUU and Taxol were 
deposited on titanium (Ti) substrates using a customized direct-write system (MicroFab 
Technologies Inc., Plano, TX). The unit consisted of a pneumatic controller, a JetDrive 
III external waveform generator, JetServer software with waveform amplifier, horizontal 
and vertical plane optic system, and a piezoelectric microvalve nozzle with a 50 micron 
orifice. Figure 3.3 (b) shows the pulse waveform applied to the nozzle to generate 
monodisperse droplets. Optimal jetting parameters for consistent deposition were chosen 
by adjusting the voltage, frequency and pulse waveform. A CCD camera with 
microscopic zoom lens was used to characterize droplet formation. Further, a motion 
controller was programmed to create a raster pattern that coats the titanium substrate 
uniformly. Each layer was allowed to dry before the next layer was deposited. Samples 
with 10 and 20 layers respectively, were deposited to obtain surface morphology data and 
release kinetics profiles.  
3.6.3 Characterization of Release 
Drug release profiles were characterized using an ultraviolet-visible spectrum 
(UV-Vis) spectrophotometer (Shimadzu UV-2450). Samples were placed in 3mL of 
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Dulbecco’s Phosphate Buffer Saline (DPBS) to initiate drug release. 10% v/v of ethanol 
was mixed in the DPBS (Fisher Scientific) to obtain accelerated release kinetics of the 
drug. The solution was shaken for several minutes to ensure a homogenous mixture. The 
peak absorbance of paclitaxel was confirmed at 230nm. Coated Ti sample readings were 
obtained at this wavelength after being shaken in an incubator shaker bath at 37°C for 2 
hours. DPBS solutions from the Ti samples were extracted into a micro-cuvette to 
observe the absorbance readings for different polymer and Taxol concentrations. 
Readings were taken every two to three hours for the first twenty-four hours and daily 
thereafter.  Release kinetics results were recorded for a period of 35 days.  
3.7 Controlled Release Coatings (Phase 2) 
3.7.1 Experimental Design and Analysis  
 Release profiles were to be obtained for a total of four different drug-loaded 
polymer systems using Polyester urathane urea (PEUU) and the bioreactive agent 
Paclitaxel (Taxol).  Two primary factors were controlled to determine their effects on the 
release profiles obtained.  The first factor was drug concentration.  Concentration was 
tested at two levels, 5% and 10% weight per volume. Lastly, the layer thickness, which 
corresponds to the number of passes, was tested at two levels, ten (10) and twenty (20) 
passes, respectively Table 3.3.   
 
 
 
 
 
 
 
 
62  
  Table 3.3 Phase 2 descriptions of experiment types for controlled release coatings 
 
 A total of three samples were coated for each experiment.  A single experiment 
consisted of a specified drug concentration having a certain layer thickness.  For 
example, 0.5% PEUU loaded with 5% taxol at 10 passes describes one experiment where 
0.5% PEUU loaded with 10% taxol at 20 passes describes another. 
 The dependant variables in the study of release profiles are identified as the 
percentage burst release and the total amount of the drug released at the end of the sample 
collection period.  The initial rate of release corresponds to the slope of the release profile 
in the initial stages.  This initial rate is relevant to the speed at which the initial burst 
takes place from the time the release period is initiated until the time it reaches a steady 
rate of release.  The percentage burst release corresponds to the ratio of drug that is 
released and drug loaded during the initial burst period.  The total release remains as 
stated above.   
The basic research question is as follows, “Can direct-write inkjet printing 
technique be used as a mechanism for depositing uniformly distributed layers of drug-
loaded polymer thin films and furthermore, can tunable drug release profiles be obtained 
over extended time periods by varying the two main input factors (drug concentration 
and coating thickness)?”  A set of more specific research questions was extracted that 
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was expected to help answer the basic research question.  These questions are stated 
below followed by their respective null and alternative hypothesis statements.   
1. Does drug dosage and coating layer thickness have a significant effect on the drug 
release profile? (Phase 2a) 
2. Does drug dosage and coating layer thickness have a significant effect on cell 
inhibition? (Phase 2b) 
3. Does drug dosage have a significant effect on blood compatibility? (Phase 2c) 
 For Phase 2a, a 2x2 factorial design was used to determine the main and 
interaction effects of the two experimental factors (i.e. drug dosage and coating 
thickness) on the response variables.  There were a total of four experiment combinations 
and each was replicated twice to assess error.  Thus, giving a total of 8 experiment trials.  
The following null and alternative hypotheses were formed:  
H01 = the sample means for drug dosage are equal 
H02= the sample means for number of layers are equal 
H03 = there is no interaction effect 
H11 = at least one of the sample means for drug dosage is different 
H12= at least one of the sample means for number of layers is different 
H13 = an interaction effect is present 
 In Phase 2b, a one-way ANOVA was conducted to determine if there was a 
difference in means between each experiment type and its respective control.  There were 
a total of 8 treatment conditions (4 controls and 4 treated surfaces) and each was 
replicated 4 times giving a total of 32 runs.  The metabolic means of samples containing 
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10 and 20 layers with a 5% w/w drug loading were compared to the metabolic means of 
samples having 10 and 20 layers of PEUU with no drug respectively.  Also, the metabolic 
means of samples containing 10 and 20 layers with a 10% w/w drug loading were 
compared to the metabolic means of samples having 10 and 20 layers of PEUU with no 
drug respectively.  Lastly, the metabolic means of each of the experiment groups was 
compared with the mean metabolic index of cells cultured on Tissue Culture Polystyrene 
(TCPS).  The following null and alternative hypotheses were formed: 
H0 = the sample means for all experiment condition are equal 
H1= at least one of the sample means is different 
 For Phase 2c, a one-way ANOVA was used to determine if drug concentration 
has a significant effect on the blood platelet count.  For this experiment each of the 
samples were coated with 20 layers of PEUU and only the drug concentration were 
varied.  There were three levels, which were 5% w/w, 10% w/w and no drug (low 
control).  The experiment was replicated three times for considering error resulting in a 
total of nine replications. The following null hypothesis was formed to state that there is 
no difference between the mean platelet count of each sample group.  The associated 
alternative hypothesis states that there exists a difference between means of the sample 
groups:  
H0 = the sample means for drug dosage are equal 
H1= at least one of the sample means for drug dosage is different 
3.7.2 Experimental Procedure  
3.7.2.1 Materials Synthesis 
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Polyester urethane urea (PEUU) and the metallic substrate (titanium) were 
generously donated by Wagner Laboratory at the McGowan Institute for Regenerative 
Medicine.  Paclitaxel, >99.5% (taxol) was obtained from L C Laboratories and 
hexaflouor-2-propanol, >99.8% (HFIP) was obtained from Sigma-Aldrich. Under a hood, 
20 milliliters of HFIP solvent were measured by micropipette and placed into a glass 
vessel.  For experiment sets one and three, 0.5% w/v (0.1 grams) of solid PEUU polymer 
was weighed using a Metler Toledo AX DeltaRange digital scale and fully dissolved in 
the previously measured HFIP to obtain a homogenous HFIP/PEUU solution.  A 5% w/w 
(0.005 grams) dosage of paclitaxel was then weighed using a digital scale and dissolved 
into the HFIP/PEUU solution.   
For experiment sets two and four, 0.5% w/v (0.1 grams) of solid PEUU polymer 
was weighed using the Metler Toledo AX DeltaRange digital scale and fully dissolved in 
a separate glass vessel containing a previously measured 20 milliliters of HFIP to obtain a 
homogenous HFIP/PEUU solution.  A 10% w/w (0.01 grams) dosage of Paclitaxel was 
then weighed using a digital scale and dissolved into the HFIP/PEUU solution.  The 
solutions were shaken vigorously in a mini shaker to ensure that a homogeneous 
HFIP/PEUU/Paclitaxel solution was obtained.  The solutions were filtered using 0.22-
micron micropore Teflon filters into two milliliter jetting reservoirs and refrigerated until 
ready for use.   
A third solution was prepared consisting of 0.5% w/v HFIP/PEUU mixture.  This 
solution did not contain the drug, paclitaxel and was stored for use as a control for the 
cell inhibition and blood compatibility testing samples.   
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 As a release media, DPBS containing 10% ethanol was chosen to simulate 
accelerated release.  One package containing 9.6 grams of Dulbecco’s Phosphate Buffer 
Saline (DPBS) powder (Fischer Scientific) was dissolved in 900 milliliters of deionized 
water to make a 900-milliliter DPBS solution. 100 milliliters of pure ethanol was then 
measured and mixed with the DPBS solution to obtain a 10% DPBS plus ethanol 
solution. The solution was shaken for one minute to ensure a homogenous mixture. 
3.7.2.2 Sample Preparation and Coating 
 Titanium sheets cut into 10x10 mm coupons.  The samples were submerged into a 
glass vessel containing pure acetone and sonicated in a bath sonicator for ten minutes.  
After ten minutes the coupons were removed from the acetone and submerged into 
ethanol.  The samples were again sonicated for another ten minutes for cleaning.  The 
sample coupons were removed and air-dried.  Each sample was assigned a sample 
number and weighed for its initial starting weight.   
The customized direct-write system (MicroFab Technologies Inc., Plano, TX) 
described above was used to determine the appropriate jetting parameters for each of the 
biopolymer solutions. The unit consisted of a pneumatic controller, a JetDrive III external 
waveform generator, JetLab software with waveform amplifier, horizontal and vertical 
plane optic system, and a piezoelectric microvalve nozzle with a 50-micron orifice. Using 
the JetLab interface, the appropriate pulse waveform for consistent droplet formation was 
characterized by manipulating the rise, dwell, and fall times, as well as the voltage and 
pressure.  The JetLab interface includes a motion control component as well as a pattern 
monitor, which allows us to control length, width and thickness of the coating pattern by 
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adjusting the step size between droplets.  A CCD camera with microscopic zoom lens 
was used to characterize droplet formation.  
 Thin films were deposited onto the 10x10 titanium substrates using the direct-
write inkjet printing technique.  The drop-on-demand (DOD) procedure is a non-contact 
technique that employs the application of electrical pulses to a piezoelectric material in 
order to create uniform droplets of a desired solution.  A schematic of the deposition 
pattern (not drawn to scale) can be seen in Figure 3.8 below. 
 
(a) 
 
(b) 
Figure 3.8 Deposition pattern using array of array command (a) top (b) iso view 
 
An array of arrays command, using the newly acquired Jetlab 4 interface, was 
used to deposit the printed droplets onto the substrates.  Figure 3.9 depicts the interface 
with input parameters that result in associated pattern, which accompanies it.  The step 
(distance between drops) and pitch (drop diameter) sizes can be optimized to obtain more 
evenly distributed coating layers.  This is depicted in Figure 3.10.  The input parameters, 
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which are required, are the origin of the array which is essentially the starting point of the 
pattern based on an absolute coordinate system, the step size within arrays (x,y), number 
of steps per array (x,y), offset between arrays (xy), number of arrays (x,y) and angle.  A 
0.05 mm step size was employed when coating our samples. The number of layers was 
input in the “number of arrays” and the offset between origins was set to zero.   
 
Figure 3.9 Depiction of JetLab print pattern interface 
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Figure 3.10 Schematic of step and pitch distance 
 
3.7.2.3 Characterization of Release 
To initiate accelerated release of the taxol drug, each sample consisting of the 
titanium alloy coated with the PEUU and Paclitaxel thin film was placed into a glass 
vessel containing two milliliters of Delbuco’s Phosphate Buffer Saline (DPBS) + 10% 
Ethanol solution.  The vessel and its contents were then placed into a Thermo Scientific 
Shaking Bath (Figure 3.11), set at 37 degrees Celsius and rotating at 50 rpm (mimicking 
conditions of the human body).  After the first 2 hours, the first reading was obtained to 
determine release of the anti-proliferative cancer drug. Following the first sample reading 
at two hours, readings were obtained four more times during the course of the first 24-
hour period at 4, 6, 22, and 24 hours.  Sample readings were again obtained at 26, 48, 72, 
98, 170, 242, and 338 hours.  Further readings were taken every 2-3 days based on 
release trends. 
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Figure 3.11 Depiction of thermo scientific shaker bath 
 
 
Figure 3.12 Depiction of Shimadzu UV-2450 spectrophotometer 
 
Release kinetics for the characterization of release profiles were measured using 
Ultra-Violet spectrophotometry techniques.  This technique is generally used to detect 
traces of a given substance within a sample by transmitting a source of light through its 
contents to measure its absorbance.  The absorbance is measured over a given 
wavelength.  Literature states that the wavelength for which the maximum absorbance 
reading for paclitaxel may be obtained is around 227 nm (Willey et. al, 1993).  The 
wavelength values found in literature for achieving the optimal absorbance readings for 
the samples were validated to ensure repeatability.  Performing serial dilutions of the 
concentrated substances and gaining sample readings from the UV spectrophotometer 
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resulted in the development a standard curve.  The release values obtained were then 
compared to the release values on the standard curve. 
As described in earlier sections the Shimadzu UV-2450 Spectrophotometer 
(Figure 3.12) was used for our sample data collection.  During these periods, sample 
aliquots from each of the vessels containing the titanium samples were extracted and 
pipetted into a microcuvette.  The microcuvette was then placed into spectrophotometer 
and the absorbance peaks were detected and recorded. 
3.7.2.4 Blood Collection and Compatibility Test 
The care and use of laboratory animals was performed according to NIH 
guidelines (Wagner Lab, University of Pittsburgh).  Fresh ovine blood was collected from 
healthy ovines by jugular venipuncture into a syringe containing heparin (Hep 6U/ml).   
Each of the samples, PEUU containing no taxol, PEUU containing 5% taxol, and PEUU 
containing 10% taxol, were placed into blood collection tubes and containing the 
heparinized ovine blood and incubated at 37º C on a hematology mixer with continuous 
rocking.  This is depicted in Figure 3.13.   
Following the blood contact procedure, the samples were rinsed with PBS.  To fix 
the samples surface containing the adhered platelets, the samples were immersed in a 
2.5% glutaraldehyde solution for two hours at 4ºC.  The samples were then serially 
dehydrated by increasing ethanol concentrations and coated using sputter deposition with 
gold/palladium.  Each sample was then observed using scanning electron microscopy. 
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Figure 3.13 Blood platelet deposition in hematology mixer 
 
The number of platelets deposited on the samples surfaces was quantified by a 
lactate dehydrogenase (LDH) assay with an LDH Cytotoxicity Detection Kit.  The 
number of cells/mm2 was determined for each sample in the sample group and the 
average and standard deviation obtained.  The statistical significance between the sample 
groups was determined using ANOVA followed by post-hoc Newman-Keuls testing of 
specific differences based on the hypothesis formally stated. 
3.7.2.5 Cell Growth Inhibition 
All coated titanium disks (6 mm diameter) were placed in a 96-well cell culture 
plate and then sterilized under UV irradiation for three hours in a biological hood. Tissue 
cultured polystyrene (TCPS) and uncoated titanium disks were set as controls. 2*103 rat 
smooth muscle cells (RSMCs) per well were seeded on the sample surface, and cell 
culture medium (DMEM supplemented with 10% FBS and 1% antibiotics) was 
exchanged every two days. MTT assay was performed to detect cellular viability at one, 
four and seven days. Briefly, 20 uL MTT solution (3 mg/mL) was added into the culture 
73  
medium in a well. After 4 hours in an incubator at 37ºC, the medium was completely 
removed and 200 uL of DMSO was added to dissolve the produced blue crystal. The 
absorbance was detected using a 150 uL dye solution at 540 nm on a UV spectrometer. 
Four samples were used at each time point for each group. 
3.8 Polymer Coatings for Controlling the Corrosion of Mg Alloys (Phase 1) 
 Biofunctional coatings are necessary to suit a variety of different medical 
applications. The use of the direct-write inkjet technique as a mechanism for enhancing 
the structural integrity of a given biomaterial via biofunctional coatings, namely 
magnesium and its alloys, is of growing interest.  Uses for magnesium as a biomaterial 
offers several advantages and can spread across a number of applications.  For instance, 
magnesium is essential to over 300 physiological functions within the body [85] and has 
also been identified as a potential biomaterial to facilitate bone growth and repair due to 
proven similarities of mechanical strength with the cortical bone [86]. 
 Direct-write deposition can be used to fabricate coatings where spatial 
requirements can be specified to develop coatings with specified porosity and 
degradation features for inhibiting the corrosion of magnesium alloys.  In this study, the 
intent was to investigate a variety of polymer coatings having various rates of 
degradation.  Here, the polymer type and layers of coating material were varied to assess 
coating specifications for applications in corrosion protection and controlled release of 
magnesium alloys.  Corrosion protection is essential to ensure that a polymer coating is 
applied, which can extend the life of the surgical device until its intended function is 
completed [86].  The controlled release of magnesium in the trachea can be beneficial in 
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relaxing airway cells when exposed to an environment causing inflammation [87].  
Magnesium deficiencies have also been linked to cardiovascular disease.  Thus, 
controlled release of magnesium via controlled release coatings can offer some benefit 
when applied to tracheal and cardiovascular stent devices [88].   
3.8.1 Sample Preparation 
 A magnesium alloy with the composition (Mg:90%, Zn:8.9%, Ca:0.5%, rest 
impurities) was smelted as ingots within an inert environment (argon) at our laboratory. 
The Mg alloy was used as-cast without further processing such as cold work or heat 
treatment. A flat piece (10mmx10mmx2mm) of this Mg alloy was casted into a disc-
shaped epoxy resin so that only the top surface of the Mg alloy was exposed. This 
process is because we are interested in studying the corrosion behavior of Mg alloy with 
different polymeric coatings on only the top surface without affecting the corrosion of the 
other sides. The sample top surface was then polished to eliminate the magnesium oxide 
layer. Two biodegradable polymer types, poly(lactic-co-glycolic acid) (PLGA) and 
polycaprolactone (PCL), were chosen based on their desired chemical and mechanical 
properties as corrosion barriers.  They offer advantages that include tunable degradation 
rates based on the adjustable chemical composition of lactic and glycolic acids in PLGA 
to lengthen or shorten degradation periods, lack of toxic response at the implant sites, and 
their ability to be metabolized by the body.  PCL is a tough biodegradable polyester with 
applications in tissue engineering and drug delivery. Both polymers were dissolved at 1% 
w/v in appropriate solvents to possess suitable viscoelastic properties for the coating 
process.     
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3.8.2 Sample Coating Procedure 
A custom direct-write inkjet setup (Jetlab4 - MicroFab Technologies, Plano, TX) 
was used to coat the samples. A 50 µm nozzle was used to deposit twenty (20) layers of 
polymer coating at different pitch distances (inter-drop distance). A single layer consisted 
of a raster pattern of continuously deposited droplets as shown in Figure 4.14 a and b. 
Both polymers (PLGA and PCL) were coated with different pitch distances (50µm and 
100µm) as shown in Table 3.4. One sample was left uncoated (bare Mg alloy) and used 
as the control. It was hypothesized that the coatings with larger pitch distances (100µm) 
would result in porous structure and higher corrosion rates when exposed to the media.  
 
(a) 
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(b) 
Figure 3.14 (a) Schematic of magnesium cast in epoxy resin material (b) schematic 
of deposition pattern 
 
                Table 3.4 Phase 1 description of experiment types 
Sample No. Polymer Type Pitch Distance (m) 
1 Bare (uncoated) N/A 
2 PLGA 50 
3 PLGA 100 
4 PCL 50 
5 PCL 100 
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3.8.3 Sample Immersion Test (Weight Loss) 
A 0.9% (NaCl) simulated body fluid (SBF) solution was prepared to mimic the 
human physiological environment.  For each of the five samples, 30 ml of the sodium 
chloride solution was added to a small vessel. The vessels containing the samples and the 
solution were covered with parafilm and kept inside a CO2 incubator at 37°Celsius to 
simulate human body temperature. The samples were removed from incubation at 6 hours 
and analyzed using optical microscopy and weight loss measurement.  The samples were 
removed from the sodium chloride solution and placed in a desiccator for several hours to 
undergo dehydration. After the samples were completely dry, they were weighed and 
imaged.  The samples were then replaced in a new vessel containing 30 ml of fresh SBF 
solution and incubated. This process was repeated for 12, 16, and 21hour time points. 
3.9 Polymer Coatings for Controlling the Corrosion of Mg Alloys (Phase 2) 
3.9.1 Experimental Design and Analysis 
 The question is posed, “Can direct-write inkjet printing be used as a mechanism 
for depositing uniformly distributed protective thin films?”  Furthermore, “Can these thin 
films aid in retardation of the corrodible magnesium alloy in physiological solutions?”  
More specifically, we seek to answer the following questions: 
1. Does polymer type and coating thickness have a significant effect on the rate of 
metal ion release? (Phase 2a) 
2. Does polymer-coating type have a significant effect on the percentage of LDH 
activity from Human Bronchial Epithelial Cells? (Phase 2b) 
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 In Phase 2a, three polymer types (polyetherurethane urea, polycaprolactone, and 
poly(lactic-co-glycolic acid) have been identified, each having their own unique 
molecular structure and degradation properties.  The samples were coated at varying 
thicknesses (10 and 20 passes).  Thus the independent variables are stated as being the 
polymer type (PEUU, PCL, PLGA, Uncoated) and thickness, and the dependent variable 
is the metal ion release over time.  A 2x3 factorial design was used to assess any 
differences among the means of the factor groups as well as the interaction effects 
between factors.  There were seven experiment conditions and was replicated twice to 
asses error.  Thus, there was a total of 14 experiment runs.  The following null and 
alternative hypotheses were formed: 
H01 = the sample means for polymer type are equal 
H02= the sample means for number of layers are equal 
H03 = there is no interaction effect 
H11 = at least one of the sample means for polymer type is different 
H12= at least one of the sample means for number of layers is different 
H13 = an interaction effect is present 
 A one-way ANOVA was conducted to determine any significant differences 
amongst treated coating combinations.  The means of the uncoated samples were 
excluded from this analysis. There were six experiment conditions and was replicated 
twice to asses error.  Thus, there was a total of 12 experiment runs.  The following null 
and alternative hypotheses were formed: 
H0 = the sample means for the coating combinations are equal 
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H1= at least one of the sample means for coating combination is different 
 For phase 2b, a one-way ANOVA was conducted to determine if there are 
significant differences between the sample treatment types.  In this phase of experiments 
each of the treated samples were coated with 20 layers of the various polymer types.  
Thus, this experiment contains one factor (i.e. polymer type) and 5 different levels (PCL, 
PLGA, PEUU, Uncoated, Cells only) including the low control with no magnesium 
exposure.  Each of experiment was replicated three times to assess error.  Thus, there 
were a total of 15 runs.  The following null and alternative hypotheses were formed:  
H0 = the sample means for polymer type are equal 
H1= at least one of the sample means for polymer type is different 
 The LDH samples also underwent inductively coupled plasma analysis to 
determine if there was any correlation between cytotoxicity percentage and magnesium 
ion content.  The following null and alternative hypotheses were formed: 
H0 = the sample means for polymer type are equal 
H1= the sample means for number of layers are equal 
3.9.2 Experimental Procedure 
3.9.2.1 Material Synthesis 
Polyetherurethane urea (PEUU) was generously donated by the Wagner Lab at 
University of Pittsburgh Institute of Regenerative Medicine and mixed with HFIP to 
make a 0.5% w/v solution.  Polycaprolactone (PCL), and poly(lactic-co-glycolic acid) 
(PLGA) were both donated by the Wake Forrest Institute of Regenerative Medicine.  The 
PCL arrived as a 10% w/v PCL and dichloromethane (DCM) solution and was further 
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diluted with DCM to obtain a 1% w/v solution.  A 1% w/v PLGA solution dissolved in 
acetone was prepared.   
3.9.2.2 Sample Preparation and Coating 
5x5 mm coupons of the bulk magnesium alloy were cut and polished.  The 
coupons were then set into an epoxy resin so that only the top surface of the magnesium 
sample was exposed. The surface of the sample was polished again to remove the 
magnesium oxide layer.  The samples were labeled and imaged using optical microscopy 
technique.  Samples were stored in a desiccator until it was time for the coating process. 
The custom direct-write inkjet setup (Jetlab4 - MicroFab Technologies, Plano, TX) 
was used to coat the samples. A 50µm nozzle was used to deposit twenty (20) layers of 
the polymer materials named above. A single layer consisted of a progressing back and 
forth pattern of continuously deposited droplets as shown in Figure 3.14 (b).  The 
samples were then used to conduct two different experiments, in vitro cell compatibility 
and immersion test.   
3.9.2.3 Immersion Testing 
 5x5 mm magnesium coupons were cast in epoxy resin as above.  Three polymer 
types were chosen as coating materials, PEUU, PCL, and PLGA.  For each of the 
polymer types two samples were coated with ten layers and two were coated with 20 
layers.  Two samples were left uncoated as a control.  The samples were fully immersed 
in 2 ml of DMEM + 10% fetal bovine serum + 1% penicillin strip (Figure 3.15).  
Aliquots were collected for each of the samples at 6 and 12 hours and then again at 1, 2, 
4, 5, 6, 7, and 8 days.  At the end of each time point, the old media was collected and 
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stored.  The vesicle containing the immersed sample was then cleaned and replaced with 
fresh media.  When the immersion testing process was completed, a 0.5 ml aliquot of 
each sample for the various time points was added to 9.5 ml of Tris buffer solution to 
achieve a 20 times dilution sample. 
 
Figure 3.15 Depiction of magnesium samples immersed in SBF solution 
 
 
Figure 3.16 Depiction of inductively coupled plasma equipment 
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3.9.2.4 Cell Culture 
 Normal Human Bronchial Epithelial (NHBE) cells were cultured in complete 
media, which consisted of a 50:50 mixture of BEBM/DMEM supplemented with 
antibiotics and growth factors.  The cells were rapidly thawed from liquid nitrogen in a 
37oC water bath and seeded in 6-well culture dishes fitted with rat tail collagen-coated 
polycarbonate membrane Transwell® inserts (0.4 µm pore).  Complete media (500 mL) 
was prepared by combining 250 mL of BEBM and 250 mL of DMEM into a flask with 
SingleQuot® components.  The cells were fed apically and basolaterally every other day 
until they reached 100% confluency (at approximately 7 days).  Figure 3.17 (a)-(c) shows 
cultured in cells in air-liquid interface at 100% confluency.  At that point, an air liquid 
interphase (ALI) was established by removing medium from the apical chamber and cells 
were fed basolaterally everyday for 14 days to allow full differentiation of the airway 
epithelial phenotype.  The cells were cultured at 37°Celcius in humidified air and 5% 
CO2. 
 
(a) 
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(b) 
 
(c)  
Figure 3.17 Depiction of healthy normal human bronchial epithelial cells in air 
liquid interface 
 
3.9.2.5 Cell – Surface Interface Testing 
 The Mg samples (n=3 per coating) were coated with 20 layers of polymer and 
sterilized under a laminar flow hood with a UV sterilization bulb for 15 minutes on each 
side.  Each of the samples were then assigned a well number and placed face down such 
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that the coated magnesium surface was in direct contact with the epithelial cell layer.  
Three wells were labeled as the low control, thus they were cells, which were untreated.  
Initial media samples were collected from each well at time zero and stored at -20°C for 
lactate dehydrogenase (LDH) assay and elemental analysis via inductively coupled 
plasma mass spectrometry (ICP-MS).    Fresh medium was placed in the lower chamber 
of each well and the plates were placed in incubation at 37°C and 5% CO2.   
Balolateral medium samples were collected again at one hour, four hours, six 
hours, 24 hours, and 29 hours.  During the sample collection period, 1.5 mL of the 
sample media was collected from each of the wells and placed into a small tube.  The 
tubes were labeled and frozen at -20°C.  Any remaining media was aspirated from the 
cell well and two mL of fresh media was reapplied to the lower chamber.  During this 
period, selected wells were imaged by phase contrast microscopy using an Evos xl 
inverted microscope (AMG).  After the final sample collection, the wells containing the 
untreated cells were lysed such that all LDH activity would be released.  These samples 
were then labeled as the high control and used for LDH analysis.   
3.9.2.6 LDH Assay 
Following exposure to coated Mg samples, reactions were terminated by 
removing materials from the apical surface, collection of basolateral culture medium and 
plates were wrapped in foil and stored at -80o C until needed for gene expression analysis.  
The Roche cytotoxicity detection kit was used to determine LDH release by the cells at 
the indicated time points.  This cytotoxicity detection kit measures cytotoxicity and cell 
death through the detection of LDH activity which has been released from damaged cells.  
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The low control consisted of the untreated cells (n=3) and the high control consisted of 
the lysed cells, which provided information about the maximum amount of released LDH 
activity in the cells.  The assay was performed according to manufacture’s 
recommendation and samples (in triplicate) were transferred into a 96-well plate 
according to the template found in Table 3.5 below.  
Table 3.5 96 -well sample template for LDH assay 
  
 Absorbance measurements were taken for each time point at 492 nm on a 
VersaMAX microplate reader (Molecular Devices).  To determine the percentage 
cytotoxicity, the average of the triplicates were obtained and the following equation was 
applied where exp. is the experimental value (i.e. absorbance value) obtained and high 
and low are in regards to the controls, respectively (Equation 1).  
 
Equation 1 Determination of cytotoxicity obtained from LDH absorbance values 
 
3.9.2.7 PCR Analysis 
3.9.2.7.1 RNA Extraction 
 The cell wells were thawed after being preserved at -80° C following the cell 
culture experiments.  The RNeasy RNA Extraction Kit (Qiagen, Valencia, CA) was 
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utilized for RNA extractions according to manufacturer’s instructions.   Briefly, to extract 
RNA from the NHBE cells 350 µl of RTL buffer was added to each of the 24 wells to 
lyse the cells.  Using a rubber policeman apparatus, the cells were detached from the 
membrane of the wells.  Each lysate sample was transferred into a microfuge tube and 
vortexed to remove any clumps.  Each of the samples were then homogenized by passing 
the lysate through 20-gauge (0.9 mm diameter) fitted RNase-free syringe 4-5 times.  
Next, 350 µl of 70% EtOH was added and mixed with the lysate by pipetting.  The lysate 
was then transferred into an RNeasy spin column fitted with a 2 ml collection tube and 
spun for 30 seconds at 10,000 rpm, at room temperature.  The resulting flow through 
from the collection tube was discarded.   
 The spin column was then transferred into a second collection tube and 350 µl of 
RW1 buffer was added.  The sample was spun again for 30 seconds at 10,000 rpm.  Next, 
80 µl of DNase solution was added to the center of the silica-gel membrane in the spin 
column and left to incubate at room temperature for 15 minutes.  Another 350 µl of RW1 
buffer was added to the column and spun at 10,000 rpm for 30 seconds to wash.   
 The samples were then washed twice by adding 500 µl of buffer RPE onto the 
column and spinning for 30 seconds at 10,000 rpm.  The samples were then spun at 
maximum speed for one minute to dry the columns.  RNA was then eluted by transferring 
the spin columns into a 1.5 ml microfuge tube and adding 50 µl of RNase-free water 
directly to the sample columns.  Finally, the samples were spun at 10,000 rpm for one 
minute.   
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3.9.2.7.2 Determination of RNA concentration and purity 
 Each of the RNA samples were diluted by adding one part RNA and 49 parts 
RNase-free water to obtain a 1/50 dilution. For each sample, 2 µl of diluted RNA was 
placed on to the center of a nanoplate reader. The RNA concentration was determined by 
measuring the absorption over a UV light at 260 and 280 nm.  The purity of RNA was 
calculated by determining the ratio A (260/280).  The RNA concentration (ng/µl) was 
calculated Equation 2.    
 
Equation 2 Determination of RNA concentration 
 
3.9.2.7.3 Complementary DNA (cDNA) Synthesis 
 Synthesis of cDNA was conducted according to the iScript cDNA Synthesis Kit 
(BIO-RAD, Hercules, CA) protocol.  A reaction mixture was prepared for a total volume 
of 15 µl per sample reaction.  Each reaction mixture consisted of 4 components, 4 µl of 
5x iScript Reaction Mix, 1 µl of iScript Reverse Transcriptase enzyme, X µl of Nuclease-
free water, and X µl of the RNA sample (Table 3.6).  The amount of Nuclease-free water 
and RNA sample required for each reaction were calculated based on the RNA 
concentration per sample.  The RNA concentrations and the calculated values for X µl of 
Nuclease-free water and X µl of the RNA are shown in Table 3.7 below.  Each reaction 
mix was spun for 3 seconds and incubated using an iCycler Thermal Cycler (BIO-RAD) 
for 5 minutes at 25° C, followed by 30 minutes at 42° C, 5 minutes at 85° C, and finally 
cooled at 4° C for at least 5 minutes.  Figure 3.18 shows the thermal cycler apparatus.   
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Figure 3.18 Depiction of iCycler thermo cycler from BIO-RAD 
 
            Table 3.6 Specified amounts for cDNA reaction mixture 
Reagent Amount 
5x iScript Reaction Mix 4 µl 4µl 
Total RNA Template** 1 µl Refer to Table 3.7  
iScript Reverse Transcriptase 1 µl 4µl 
Nuclease-free water q.s. 20 µl Refer to Table 3.7  
 
Table 3.7 Calculated RNA and nuclease free water required based on RNA 
concentration 
Sample Concentration Desired, µg RNA needed H20 Needed 
1 148.2 400 2.70 12.30 
2 81.5 400 4.91 10.09 
3 71.5 400 5.59 9.41 
4 48.5 400 8.25 6.75 
5 61.6 400 6.49 8.51 
6 92.3 400 4.33 10.67 
7 77.7 400 5.15 9.85 
8 71.1 400 5.63 9.37 
9 112.9 400 3.54 11.46 
10 132.9 400 3.01 11.99 
11 124 400 3.23 11.77 
12 70.3 400 5.69 9.31 
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13 140.3 400 2.85 12.15 
14 107.6 400 3.72 11.28 
15 59.8 400 6.69 8.31 
16 78 400 5.13 9.87 
17 64.6 400 6.19 8.81 
18 57.1 400 7.01 7.99 
19 49.3 400 8.11 6.89 
20 58.4 400 6.85 8.15 
21 61.7 400 6.48 8.52 
22 38.5 400 10.39 4.61 
23 34.1 400 11.73 3.27 
24 n/a n/a n/a n/a 
 
3.9.2.7.4 Measurement of Cyclooxygenase-2 (COX-2) Gene Expression  
 PCR was used to measure the COX-2 gene expression in NHBE cells exposed to 
polymer coated magnesium samples.  RNA was extracted and synthesized into cDNA as 
described above.  COX-2 primer suspended in GoTaq (23 µl) was mixed with 2 µl of the 
synthesized cDNA sample.  Beta-actin primer suspended in GoTaq (23 µl) was mixed 
with the synthesized cDNA sample and used as a reference (Table 3.8).  The PCR 
protocol was set for an initial 95°C for 4 minutes, followed by 35 cycles at 95°C for 30 
seconds, 60°C for 30 seconds and 72°C for 3 minutes.  The synthesized cDNA was 
separated on 0.8% agarose gel at 80 V for one hour.  The gel was then stained for 20 
minutes in 0.01% ethidium bromide.  The gel was imaged using Biorad Chemi-doc 
(Figure 3.19) and Image Lab interface to visualize band density.  The densitometry 
results were analyzed in order to calculate the relative expression of COX-2 against the 
beta actin genes.    
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 Table 3.8 Synthesis of Cox-2 and beta actin primers 
 
 
Figure 3.19 Depiction of BIO-RAD chemi-doc 
 
3.9.2.7.5 Statistical Analysis for Cyclooxygenase-2 (COX-2) Gene Expression 
The average volume intensity of the beta actin genes was used to obtain 
normalized values for the COX-2 expression gene.  The normalized values (n=6) were 
used to conduct statistical analysis.  A one-way analysis of variance was conducted to 
determine statistical differences between the mean cyclooxygenase-2 (COX-2) gene 
expressions of cells for each experiment type.  After determining the statistical 
differences between the experimental means, Tukey’s post hoc analysis was performed to 
determine the specific differences between mean pairs.   
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CHAPTER 4 
RESULTS AND DISCUSSION 
4.1 Jetting Optimization 
Direct Write Inkjet printing can be employed as a mechanism for depositing non-
newtonian biopolymer fluids to modify the surfaces of surgical implant devices. The 
optimal jetting parameters for 0.5% w/v PEUU were obtained by determining the 
appropriate frequency, positive/negative jetting voltage, rise time, dwell time, fall time, 
and final rise time denoted by f, +V/-V, TR, TD, TF, TFR, respectively, and the reservoir 
pressure as described above.  These obtained values are approximate values.  This is 
because of the level of difficulty in obtaining the exact value for the reservoir pressure, 
thus the remaining input values needed to be adjusted.  The final jetting parameters 
obtained at a reservoir pressure of approximately -16 psi were f = 500Hz, +V/-V = 58 V/-
58 V, TR = 51 µs, TD  = 50 µs, TF = 51 µs, and TFR = 51 µs. 
4.2 Controlled Release Coatings (Phase 1) 
Drug release kinetics and surface morphology and thickness were analyzed to 
evaluate the possible factors that might affect the release behaviors of the multilayer 
coatings. The factors of interest included: (1) polymer concentration, (2) drug loading and 
(3) the number of overprint passes.  
4.2.1 Characterization of Release   
The measured release kinetics profiles represent an accelerated curve with respect 
to time. Thus, samples under in vivo conditions would release over a longer period of 
time than those observed here. Figure 4.1 shows the release profiles for samples with 
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varying polymer, drug (taxol) and number of overprint passes as tabulated in Table 4.1. 
The nomenclature (1-5-10P-S2) corresponds to 1% PEUU, 5% taxol, 10 Passes, Sample 
2. Samples with smaller film thickness and lower drug loadings resulted in longer and 
steady rates of drug release. While, samples with higher drug loadings resulted in a high 
percentage of release during the initial burst release period. This situation was attributed 
to the burst release of crystallized taxol particles (beads) within the polymer matrix. 
Figure 4.2 (a) and (b) shows the (a) top view and (b) side view of the taxol beads with 
average diameters of 5 to 8 microns. These beads are a result of reaching the saturation 
limit of the taxol within the biopolymer solution and they indicate the upper limit for 
possible drug amount to be loaded. 
Table 4.1 Factor levels for multilayered controlled release coatings 
No. Factor Low level High level 
1 Polymer concentration (%w/v) 1 1.5 
2 (Drug) paclitaxel concentration 
(%w/w) 
5 10 
3 Number of overprint passes 10 20 
 
The higher polymer concentrations and film thicknesses (20 passes) resulted in an 
early dislodgement of the polymer thin film. This situation was due to the lack of 
adhesion between the polymer and the titanium substrate. Release readings were 
discontinued after partial dislodgement of these coatings after day 5 to eliminate 
erroneous data. However, the dislodged coatings released approximately double the taxol 
based on the higher surface area of exposure to the DPBS as compared to the adhered 
coatings. (Nomenclature: 1-5-10P-S2 stands to 1% PEUU, 5% taxol, 10 Passes, Sample 
2) 
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Figure 4.1 Phase 1 taxol release profiles for determining candidate experiment types 
 
 
(a) 
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(b) 
Figure 4.2 (a) Top view (b) Side view of crystallized taxol particles precipitated from 
polymer matrix 
 
4.2.2 Surface morphology and film thickness evaluation 
The surface morphology and film thickness of the drug loaded polymeric coatings 
were evaluated using scanning electron microscopy and the optical profilometer, 
respectively. The polymer film was cut to reveal the cross-section areas and thickness 
profiles. Figure 4.3 shows the (a) top view and (b) cross-section view of the polymer film 
with 10 passes of coatings. As can be seen from the top and cross-section views, there are 
whiskers of polymer that adhered to the Ti substrate for the lower number of passes (10). 
The average thickness for a 20-pass film obtained from the optical profilometer testing 
varied between 18 to 22 microns. However, the thickness obtained from the SEM 
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measurements was around 20 microns in thickness. The approximate coating thickness 
for each print pass was around 1 micron in thickness.  
 
(a) 
 
(b) 
Figure 4.3 (a) Top view (b) cross-section of drug loaded polymer film on Ti 
substrate 
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4.3 Controlled Release Coatings (Phase 2) 
4.3.1 Characterization of Release 
The two factors studied were taxol concentration and the number of layers.  The 
levels of taxol concentration were 5% and 10% w/v and the two levels of layer thickness 
were 10 and 20 layers.  Thus, there was a total of four experiment types (5% taxol and 10 
layers, 10% taxol and 10 layers, 5% taxol and 20 layers, 10% taxol and 20 layers).  The 
absorbance values obtained from the spectrophotometer were compared to the values of 
the standard curve and the final concentration (µg/ml) of taxol present in the samples was 
derived.  The average concentration of taxol present in the samples having 10 layers and 
containing 5% and 10% w/w of the polymer content was 26.07 µg/ml and 49.09 µg/ml, 
respectively.  For the samples coated with 20 layers and containing 5% and 10% w/w of 
taxol, the final concentrations were 31. 29 µg/ml and 83.19 µg/ml, respectively.  This 
condition is depicted in Figure 4.4.  
The experimental data were assessed to ensure that the assumptions of normality 
and randomness were satisfied.  It was determined that the data were normally distributed 
and did not exhibit any obvious trends or patterns; thus the data was, in fact, random in 
nature.  A depiction of the normality and randomness of the data sets can be found in 
figures 4.5a and 4.5b, respectively.  The statistical relevance of the independent variables 
on the total taxol concentration after 21 days was thus suitable for the application of 
analysis of Variance (i.e. ANOVA) statistical testing. 
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Figure 4.4 Taxol concentration release profile for 21-day period  
 
 
(a) 
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(b) 
Figure 4.5 (a) Normality plot (b) randomness plot for taxol release data 
 
A 2x2 factorial design was conducted to determine the main effects of the given 
factors on the total drug concentration released at the end of the sample collection period 
(i.e. 21 days). The findings showed that the variations in drug dosage and number of 
layers had strikingly significant effects (p = 0.00) on the total drug concentration released 
at p < 0.05. More specifically, the difference in data means for an increasing drug loading 
percentage was approximately 50 µg/ml and nearly 40 µg/ml for increasing the number 
of coating layers (Figure 4.6a).  The interaction plot from the DOE analysis showed that 
the combined factors were also significant (p = 0.00) with regards to the drug release 
concentration at the end of the 21 days (Figure 4.6b).  Details of the statistical output 
analysis can be found in Appendix A.  The difference in data means for the samples 
having 5% w/w drug dosage showed a slight increase (approx. 10 µg/ml) as the number 
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of passes increased from 10 to 20 layers.  Samples having 10% w/w drug dosage showed 
a more profound increase (approximately 60 µg/ml) among data means as the number of 
layers increased from 10 to 20 layers. 
 The percentage of drug released at the various time points was also obtained.  It 
was evident that the burst period for each of the sample categories fell between t = 0 and t 
= 24 hours (i.e. after 24 hours the percentage of drug reached a steady state of release).  
Thus the percentage of the total drug released after 24 hours for the samples containing 
5% and 10% w/w and 10 layers was 60.60% and 61.33%, respectively.  For samples 
containing 5% and 10% w/w having 20 layers, the percentage of total drug release was 
51.69% and 49.37%. It appeared that the samples, which contained the thinner coatings, 
had a more profound initial burst period.  The samples having the thicker layer of 
coatings appeared to have a steadier rate of release during the initial burst period.  
However, a test of statistical significance was required to determine any real differences 
(Figures 4.7 a-d). 
 
(a) 
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(b) 
Figure 4.6 (a) Main affect and (b) interaction plot for total drug release after 21 
days 
 
 
(a) 
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(b) 
 
(c)  
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(d) 
Figure 4.7 Percentage of total drug release over time for (a) 5 % taxol and 10 passes 
(b) 10 % taxol and 10 passes (c) 5 % taxol and 20 passes (d) 10 % taxol and 20 
passes 
 
 The experimental data were assessed to ensure that the assumptions of normality 
and randomness were satisfied.  It was determined that the data were normally distributed 
and did not exhibit any obvious trends or patterns. Therefore the data was random in 
nature.  A depiction of the normality and randomness data is shown in figure 4.8 (a) and 
4.8 (b), respectively.  As a result, the statistical relevance of the independent variables on 
the percentage burst release was suitable for the application of analysis of Variance (i.e. 
ANOVA) statistical testing. 
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(b) 
 
(b) 
Figure 4.8 (a) Normality plot and (b) randomness plot for percentage burst release. 
 
A 2x2 factorial design was conducted to determine the main effects of the given 
factors on the percentage of drug released during the burst period.  The burst period 
identified for analysis was between 0 and 24 hours.  The results showed that for both 
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factors (drug concentration and number of passes) there was a strikingly significant effect 
(p = 0.00) on the drug released during the burst phase at p < 0.05.  Therefore, the null 
hypothesis was rejected.  More specifically, by increasing the drug concentration from 
5% w/w to 10% w/w a visibly higher difference in the data means was realized.  
Although increasing the number of layers from 10 to 20 showed a relatively lower 
difference in data means, the differences were still significant (Figure 4.9a).  The 
statistical output pertaining to the main and interaction effects on burst release percentage 
can be found in Appendix A.   
Interactions between the two factors also had significant effects (p = 0.00) on the 
burst release percentage.  Thus any combination of the factors tested could be employed 
to achieve the desired drug release behaviors during the initial release period.  Results 
showed that for the samples containing 5% w/w of drug loading, the data means showed 
a marginal decrease in the percentages the drug released during the burst period as the 
number of layers was increased from 10 to 20.  For the samples with a 10% w/w drug 
loading, the samples showed a significant increase in the percentage drug release during 
the burst period as the number of layers was increased from 10 to 20 (Figure 4.9b).   
4.3.2 Blood Collection and Compatibility Test 
SEM micrographs taken at 500X and 2,000X show that evenly distributed clusters 
of platelets have attached to only the sample control surfaces containing PEUU only.  
Micrographs were also obtained for the samples containing 5% and 10% w/w of the taxol 
drug.  One can visually see the decrease in adhering platelets as the taxol concentration is 
increased.    
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(a) 
 
(b) 
Figure 4.9  (a) Main and (b) interaction affects plot for percentage of total drug 
released during the burst release period 
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Platelet deposition onto the sample surfaces was determined by LDH assay. 
Samples containing PEUU with no taxol drug were fabricated as a control (Figures 4.11a 
and b).  The data was presented as means with standard deviation.  The average number 
of platelets was 10,191 cells/mm2 with a standard deviation of 1,194. The sample with 
PEUU containing 5% taxol visually showed a decrease in platelet deposition compared to 
the control and the sample containing 10% taxol showed more sparse platelet deposition 
compared to the control (Figure 4.12-4.13a and b).  The average platelet count with 
standard deviations for the 5% and 10% sample were 4,637 cells/mm2 (1,339) and 3,933 
cells/mm2 (3,933), respectively.   
 
Figure 4.10 Statistical significance of drug concentration of blood platelet deposition 
 
The statistical significance among sample groups was determined using One-way 
Analysis of Variance (ANOVA).  Post-hoc Newman-Keuls testing was performed to 
determine specific differences.  Statistical significance among the samples containing 
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only PEUU (control) and both sets of samples containing 5% and 10% taxol embedded in 
PEUU were found to exists at p < 0.05.  Thus, the p- value to determine statistical 
significance between the control and the sample containing 5% taxol was 0.016376.  This 
value is below 0.05. Therefore, the addition of a 5% w/w taxol drug loading had a 
statistically significant effect on platelet adhesion.  The resulting p-value to determine 
statistical significance between the control and the sample containing 10% was 0.022789 
(Figure 4.10).  This value was also lower than the standard p < 0.05.  Thus, the addition 
of a 10% w/v taxol concentration also had a significant effect on platelet adhesion (Table 
4.2).  The results also showed that the difference between the additions of 5% taxol 
versus the addition of 10% taxol was insignificant.   
Table 4.2 Specific significance between groups for blood platelet deposition 
 
4.3.3 Inhibition of Rat Smooth Muscle Cells  
 The metabolic means of samples containing 10 and 20 layers with a 5% w/v drug 
loading were compared to the metabolic means of samples having 10 and 20 layers of 
PEUU with no drug, respectively.  In addition, the metabolic means of samples 
containing 10 and 20 layers with a 10% w/v drug loading were compared to the 
metabolic means of samples having 10 and 20 layers of PEUU with no drug respectively.  
Lastly, the metabolic means of each of the experiment groups were compared with the 
mean metabolic index of cells cultured on Tissue Culture Polystyrene (TCPS). 
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(a) 
 
(b) 
Figure 4.11 Platelet deposition for control, PEUU with no drug loading (a) 500x (b) 
2,000x 
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(a) 
 
(b) 
Figure 4.12 Platelet deposition on PEUU coating with 5% taxol concentration (a) 
500x (b) 2,000x 
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(a) 
 
(b) 
Figure 4.13 Platelet deposition on PEUU with 10% drug loading (a) 500x (b) 2,000x 
 
 The TCPS materials were used in the cell culture to encourage cell proliferation 
across the substrate.  Thus, the metabolic index here is the natural metabolic index from 
cells as they were cultured over a 1, 4, and 7 day period.  As compared to the cells 
111  
cultured on bare titanium substrate there was a slight increase in metabolic index.  The 
TCPS samples were also compared to samples coated with 10 and 20 passes of PEUU 
without any drug loading and results showed an even further increase in metabolic 
activity for the 20 layer coatings.  This fact indicates that there was an increase in cell 
count where a 20-layer coating was present, which means that the cells can adapt to the 
polymer coating itself.  A description of this situation is shown in Figure 4.14.   
 
Figure 4.14 Statistical significance of controlled release experiment types on cell 
inhibition 
 
 In this research, it was hypothesized that taxol-loaded PEUU coatings would be 
used to inhibit cell proliferation of undesired cancer cells based on increased coating 
material and drug dosage.  The results showed that there was a statistically significant 
difference between the control groups (i.e. TCPS, bare Ti, 10 layers of PEUU, and 20 
layers of PEUU) when compared to each of the respective experiment groups.  For 
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example, after 4 and 7 days there was a significant decrease in metabolic activity when 
5% and 10% w/w of taxol were added to 10 layers of PEUU.  The same finding is true 
when 5% and 10% w/w of taxol was added to 20 layers of PEUU.  However, there does 
not appear to be a significant difference between the various experimental groups.   
 We proposed that the direct-write technique could be used to deposit a variety of 
other non-newtonian biopolymer fluids encompassing a variety of therapeutic agent for 
drug delivery.  However, studies must be conducted to study the release profile of a given 
agent from a given polymer coating type.   
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CHAPTER 5 
RESULTS AND DISCUSSION 
5.1 Jetting Optimization 
The direct-write inkjet technique was used to deposit non-newtonian biopolymer 
fluids for controlling the corrosion of magnesium alloys. The optimal jetting parameters 
were obtained by determining the appropriate frequency; the positive/negative jetting 
voltage, rise time, dwell time, fall time, and final rise time denoted by f, +V/-V, TR, TD, 
TF, TFR, respectively, and reservoir pressure.  These obtained values are approximate 
values.  This is because of the level of difficulty in obtaining the exact value for the 
reservoir pressure. Thus the remaining input values needed to be adjusted.  The final 
jetting parameters obtained for PEUU at a reservoir pressure of approximately -16 psi 
were f = 500Hz, +V/-V = 58 V/-58 V, TR = 51 µs, TD  = 50 µs, TF = 51 µs, and TFR = 51 
µs.  For PCL, the final jetting parameters obtained at a reservoir pressure between -8 psi 
and -12 psi were f = 500Hz, +V/-V = 42 V/-42 V, TR = 22 µs, TD  = 25 µs, TF = 38 µs, 
and TFR = 22 µs. For PLGA, the final jetting parameters obtained at a reservoir pressure 
between -8 psi and -12 psi were f = 500Hz, +V/-V = 32 V/-32 V, TR = 22 µs, TD  = 32 µs, 
TF = 24 µs, and TFR = 22 µs. 
5.2 Polymer Coatings for Controlling the Corrosion of Mg Alloys (Phase 1) 
 Immersion testing was terminated at 21 hours, as the bare Mg alloy surface 
showed severe pitting and corrosion, thus was defunct for implantable conditions. It is 
important to note that the corrosion conditions for samples are at an accelerated pace as 
compared to the actual implant conditions. This situation occurs because implants are in 
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prominent contact with tissue and bone structures with relatively lower liquid interface 
from the site blood vessels. In contrast, the tests were conducted in complete liquid 
immersion to simulate longer durations in actual implant conditions. 
 
Figure 5.1 Cyclic corrosion mechanism in magnesium alloy samples 
 
5.2.1 Cyclic Corrosion Mechanism in Mg Alloy Samples 
In a typical corrosion reaction, the Mg alloy reacts with water leading to 
magnesium hydroxide and the release of hydrogen gas. This process is shown in Equation 
(3).  The uncoated magnesium sample showed a cyclic corrosion mechanism as seen in 
figure 5.1. During the initial six hours exposed magnesium alloy surface underwent 
corrosion with the formation of magnesium hydroxide Mg(OH)2 products on the surface.  
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Equation 3 Chemical reaction for magnesium hydroxide 
 
The corrosion products resulted in an increase in the weight of the sample. 
Further, at 12hrs duration the corrosion products detached from the underlying sample 
into the SBF resulting in weight loss of the sample. The freshly exposed surface of the 
sample underwent subsequent corrosion and formation of Mg(OH)2 products at 16hrs. 
Finally, at 21hrs these corrosion products detached resulting in severe pitting and 
degradation of the underlying sample as seen in Figure 5.2 (right). Though, the bare 
sample has incremental weight gains during corrosion, it is evident from the Figure 5.1 
that the overall trend is downward (weight loss) indicating cumulative weight loss of Mg 
alloy. 
The PLGA based polymeric coating with 100-micron deposition spacing shows 
weight loss at 6 and 12 hours, respectively. This fact was attributed to the degradation of 
the PLGA coating during the initial period. The larger spacing of the deposited 
microdroplets formed a porous coating allowing media to infiltrate within the layers. At 
16hrs the PLGA-100 coating shows weight gain due to the formation of corrosion 
products within the film when in contact with the entrapped media. Further, at 21hrs a 
particular region within the coating film detaches (Figure 5.3) allowing the corrosion 
products to escape. Thisprocess results in a weight loss from the PLGA-100 sample. 
The PLGA-50 sample with tighter deposition pattern showed lower weight loss 
and corrosion behavior as compared to the PLGA-100 coating. This fact is due to PLGA-
116  
50 coating is less porous and offers resistance to media infiltration. During the initial 
12hr period, there was weight loss due to the degradation of the PLGA film. Further, at 
16hrs corrosion products are formed within the PLGA-50 film at specific locations 
resulting in weight gain. This process is followed by a release of Mg alloy degradation 
product through the porous sections of the PLGA-50 film (Figure 5.4) at 21hrs and 
subsequent weight loss. 
PCL (Polycaprolactone) is a tough biodegradable polymer with enhanced 
mechanical properties and chemical stability as compared to PLGA. Similar trends of 
initial weight loss (12hrs) due to polymer degradation were observed with the PCL-50 
coating. This process was followed by Mg alloy degradation and weight gain as shown in 
Figure 5.1. Finally, at 21hrs duration, the degradation products were released to the 
media resulting in weight loss. It is important to note that the corrosion mechanism for 
PCL-50 is analogous to PLGA-50 the overall weight loss was lower in the former case. 
This is due to the enhanced film stability of PCL-50 as shown in Figure 5.5. 
 
 
Figure 5.2 Uncoated magnesium alloy (left) before t=0 and (right) after t=21 hours 
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Figure 5.3 PLGA-100 Mg alloy (left) t=0 and (right) t=21 hours 
 
 
 
 
 
Figure 5.4 PLGA-50 Mg alloy (left) t=0 and (right) t=21 hours 
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Figure 5.5 PCL-50 Mg alloy (left) t=0 and (right) t=21 hours 
 
 
  
Figure 5.6 PCL-100 Mg alloy (left) t=0 and (right) t=21 hours 
 
The PCL-100 coating had higher porosity and resulted in media infiltration during 
the initial 6hr period. However, because the PCL film has better adhesion properties to 
the Mg substrate, the corrosion products were retained within leading to a weight gain.  
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During the next 10hrs (6 to 16hrs) there was weight loss due to PCL degradation and the 
release of corrosion products through the porous film. This situation led to exposure of 
the underlying Mg alloy surface to fresh media resulting in corrosion products (Figure 5.6 
right) and subsequent weight gain at 21hrs.  
5.2.2 Total Weight Loss/Gain in Mg Alloy Samples 
 
Figure 5.7 Weight loss/gain of various sample types 
 
It is important to note the caveat that the polymeric coatings show higher weight 
loss as compared to bare Mg alloy. This situation is attributed to the combination of the 
weight loss of the polymer and Mg corrosion products, with the former being a 
significant proportion of the total weight loss. As can be seen from Figure 8 the sample 
PLGA-100 has the highest weight loss due to high corrosion rate and degradation of 
porous PLGA film. PLGA-50 and PCL-50 show comparable weight loss due to lower 
corrosion rates. PCL-100 shows weight gain at 21 hrs due to the retention of corrosion 
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products within the PCL film. It is important to note, that corrosion cycles for different 
samples may not coincide at the same time point. For example, PLGA is a fast degrading 
polymer and may gain and lose weight at frequent intervals as compared to PCL.  
5.2.3 Corrosion Metrics Based on Polymer Type and Pitch Distance 
Table 5.1 Corrosion impeding properties of polymer coatings 
Polymer Type Degradation Properties Corrosion 
Rate of Mg 
alloy 
PCL Tough biodegradable polyester with slower 
dissolution characteristics 
Low 
PLGA Tunable degradation rates based on the 
adjustable chemical composition of lactic and 
glycolic acids within polymer 
 
High 
 
Table 5.2 Relationship between pitch distance and corrosion rate 
Pitch Distance Porosity Corrosion 
Rate of Mg 
alloy 
50 Dense polymer microstructure with close 
overlap 
Low 
100 Lower overlap and presence of permeable 
polymer layers 
High 
 
Table 5.1 shows differences in the corrosion behavior of the Mg alloy surface 
based on the polymer type. PCL serves as a more robust polymer to protect the 
underlying Mg alloy surface from corrosion as compared to PLGA. However, the PLGA 
polymer may have tunable degradation rates, which are obtained by varying the ratio of 
lactic and glycolic acids within the polymer. Thus, depending on the application intent, 
one can employ either of these polymers to obtain controlled corrosion behavior. Table 
5.2 shows the relationship between pitch distance (interspacing of deposited polymer 
microdroplets on substrate) and the corrosion rate of the Mg alloy surface. As shown in 
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Table 5.2, larger pitch distances (100µm) lead to porous polymer layers resulting in 
infiltration of the biological media to the Mg alloy surface. Thus, higher corrosion 
products are formed at this pitch distance for both the polymer types. On the contrary, 
tighter pitch distances (50µm) form dense and homogeneous polymer microstructures 
prolonging the life of the polymer coatings and lowering the corrosion of the underlying 
Mg alloy surface. These metrics play an important role in determining the choice of 
polymer type and pitch distance to control Mg alloy corrosion for specific implant 
applications.   
5.3 Polymer Coatings for Controlling the Corrosion of Mg Alloys (Phase 2) 
5.3.1 Immersion Testing (ICP) 
The samples were immersed in simulated body fluid (SBF) to initiate the 
corrosion process.  Sample aliquots taken at each of the specified time points were then 
tested for magnesium ion presence by inductively coupled plasma (ICP) elemental 
analysis.  The immersion test was stopped after 8 days due to peeling of the polymeric 
coating.  The effect that coating thickness (10 versus 20 layers) had on magnesium ion 
presence was compared among all polymer types.  For example, a comparison between 
10 layers of PEUU and 20 layers of PEUU was made to determine the effects of layer 
thickness for this polymer type on the magnesium presence.   
For the PEUU sample coated with 10 and 20 layers, 0.0010 mol/L and 0.0028 
mol/L of magnesium was present in the SBF solution, respectively (Figure 5.9).  Samples 
coated with 10 and 20 layers of PLGA showed a 0.004 mol/L and 0.0016 mol/L 
magnesium presence in SBF, respectively (Figure 5.10). For the PCL sample coated with 
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10 and 20 layers, 0.0026 mol/L and 0.0059 mol/L of magnesium was present in the SBF 
solution, respectively (Figure 5.8).  Therefore, it is shown that coating thickness does 
have some effect on magnesium presence.  However statistical analysis was necessary to 
determine if the differences were significant. 
It is apparent through the data analysis that for the PCL coating, an increase in the 
polymer material resulted in an adverse effect on the magnesium ion content that was 
ultimately released into the SBF solution after the 8-day immersion period (Figure 5.8).  
This phenomenon is explained because of the materials tendency to adhere to the surface 
of the magnesium alloy. Thus, maintaining any fluid and corrosion byproduct that may 
have seeped through the polymer coating.  The fluid entrapped within the polymer 
coating causes increased corrosion of the magnesium alloy material.   
 
Figure 5.8 Magnesium content comparison of layer thickness for PCL coating 
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Figure 5.9 Magnesium content comparison of layer thickness for PEUU coating 
 
 
Figure 5.10 Magnesium content comparison of layer thickness for PLGA coating 
 
A comparison between the uncoated magnesium sample and the samples coated 
with 10 layers of each polymer type was noted after an 8-day immersion period.  For the 
uncoated sample, the amount of magnesium present in the SBF solution was 0.0078 
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mol/L.  For the coated samples, both PCL and PEUU offered the best protective coatings 
having 0.0026 mol/L and 0.0028 mol/L magnesium presences respectively.  The PLGA 
coating was shown to be the least protective coating with 0.0040 mol/L.    
A comparison between the uncoated magnesium sample and the samples coated 
with 20 layers of each polymer type was also noted.  This is shown in figure 5.11.  For 
the uncoated sample the amount of magnesium present in the SBF solution was 0.0078 
mol/L.  For the coated samples, PEUU offered the best protective coating and a more 
consistent rate of corrosion having 0.0010 mol/L mg presences.  The PLGA coating was 
also found to be a good protective coating with 0.0016 mol/L.   The corrosion rate of the 
PCL coating was more comparable to that of the uncoated sample.  It was evident that 
varying the levels of each of the identified factors did have some effect on the 
magnesium content present in the SBF solution, however statistical analysis was 
necessary to determine tany significant differences.   
 
Figure 5.11 Magnesium content comparison between all treatment types 
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 The experimental data were assessed to ensure that the assumptions of normality 
and randomness were satisfied.  It was determined that the data were normally distributed 
and did not exhibit any obvious trends or patterns, thus the data was, in fact, random in 
nature.  The normality and randomness plots for data comparing the polymer coating 
types amongst each other are depicted in figures 12a and 12b, respectively.  As a result, 
the statistical relevance of the independent variables on magnesium ion content was 
suitable for the application of analysis of Variance (i.e. ANOVA) statistical testing. 
 A 3x2 factorial analysis was conducted to compare the effects of the polymer type 
and number of printed layers on the magnesium ion presence after the 8-day immersion 
period.  Therefore, the uncoated samples were omitted from this analysis.  The results of 
the analysis revealed that there is no actual significant effect amongst the polymer 
coating types.  However, the main effects plot is consistent with the results, which shows 
that between the three coating types differences do exists although they may not be 
significant (Figure 5.13a).  Here again, it is shown that PEUU offers the best protective 
coating followed by PLGA and PCL.   
The interaction plot reveals also that increasing the number of layers of PLGA 
and PEUU offers better corrosion protection whereas increasing the number of PCL 
layers from 10 to 20 results in an increase in corrosion byproduct when fully immersed in 
the SBF solution (Figure 5.13b).  For matching magnesium degradation to bone growth 
or repair, PCL should be eliminated as a possible surface coating material, as it does not 
significantly reduce the rate of corrosion.  Details of the factorial design for magnesium 
ion content are shown in Appendix C. 
126  
 
(a) 
 
(b) 
Figure 5.12 (a) Normality plot and (b) Randomness plot for data comparison 
amongst polymer coating types 
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(a) 
 
(b) 
Figure 5.13 (a) Main and (b) interaction affect plots for polymer type and layer 
thickness amongst polymer coating types 
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 The experimental data were assessed to ensure the assumptions of normality and 
randomness were satisfied.  It was determined that the data were normally distributed and 
did not exhibit any obvious trends or patterns, thus the data was, in fact, random in 
nature. Normality and Randomness for data comparisons between all sample treatment 
types were validated and can be found in figures 5.14a and b, respectively.  As a result, 
the statistical relevance of the independent variables on magnesium ion content was, 
again, suitable for the application of analysis of Variance (i.e. ANOVA) statistical 
testing. 
A One-way ANOVA was conducted to compare each experiment type against the 
control (uncoated) for statistical significance.  The results of this analysis showed that 
there was a statistical difference between at least two of the sample means given p = 
0.036 which is less than the specified alpha level of 0.05 (Appendix C).  A Tukey’s post 
hoc analysis was conducted to determine exactly which of the data means were 
statistically different.  A depiction of the differences between the data means is shown in 
figure 5.15.  The result from the Tukey analysis showed that the difference in the data 
mean for the uncoated samples was statistically different from the mean samples coated 
with 20 passes of PEUU.  This finding was consistent wit the hypothesis that the PEUU 
coating would provide the most corrosion protection for the magnesium alloy.  This 
coating could be applied for controlled release of magnesium for cardiovascular and 
tracheal stent applications.  There was no significant affect on the magnesium content for 
all other experiment categories.   
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(a) 
 
(b) 
Figure 5.14 (a) Normality plot and (b) randomness plot for data comparison of all 
samples types 
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(b) 
Figure 5.15 Box plot for ICP data depicting differences in data means 
 
5.3.2 Biocompatibility of Polymer Coated Magnesium Alloys 
 LDH activity was assessed as previously described.  Due to the variation between 
the cultured cells in each well, the cytotoxicity levels from the LDH assays were 
converted to percentage of the high control values.  This was so that each of the samples 
could be compared to the total possible LDH activity.  The treated samples were also 
compared to the percentage LDH activity of the low control samples, which saw no 
exposure to the magnesium alloy.   
 LDH activity was collected over the course of a 24 hour period at t = 0, 1, 4, 6, 
and 24 hours.  The sample data collected at time zero represents two distinct events.  The 
first was that this sample was collected at the end of a 24-hour period prior to initiation of 
the experiment.  This was to gauge LDH release over a one-day period.  This is apparent 
in the graph shown below which depicts a sample reading that shows significantly higher 
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LDH activity when compared to subsequent readings.  Also, at time zero fresh media was 
added to each of the sample wells to initiate the new testing period.  Thus, it is taken that 
each time point represents the end of a sample collection period.   
 First it is necessary to describe the pattern of LDH activity of the low control 
samples (i.e. samples unexposed to the magnesium alloy).  From t = 0 to t = 1 hour, an 
apparent decrease in LDH activity was observed.  During the one-hour period the cells 
seemed to be undisturbed thus not much LDH release had occurred.  At t = 4 the media 
captured LDH activity for a slightly longer time period (i.e. three hours) and as a result 
slightly higher levels of LDH activity was recorded.  After 24 hours, the cell media 
collected LDH activity for 18 hours thus there is a large spike in LDH activity.  It is 
important to note that the cultured NHBE cells were cultured for 23 days, which included 
conversion into air liquid interface.  Thus, the cells were expected to show some signs of 
stress irrespective of magnesium exposure around 24 hours after reaching confluency.   
 For the cultured wells containing the various treated sample types, results show 
that between t = 1 hour and t = 6 hours the cells seem to be responding in a similar 
manner irrespective of the treatment type.  However, the cultures containing polymer 
coated samples showed decreasing LDH activity as compared to the samples containing 
no magnesium exposure (cells only), which showed increases in LDH release.  This is an 
indication that the cells are responding positively to magnesium exposure.  At the next 
sample collection, t = 24 hours, all of the well containing the various treated samples 
show an increase in LDH release.  The data analysis was cut of at the 24-hour time period 
due to the naturally declining health of the cells in air-liquid interface.  Also, the 
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difference of time between the 24-hour time point and the 29-hour time point was not 
enough time to collect relevant amounts of LDH activity.  A depiction of LDH activity 
collected for each time point is shown in figure 5.16.   
The cells, which were exposed to the uncoated magnesium surface, showed the 
least amount of LDH activity. To explain this phenomenon, one could say that more 
magnesium exposure contributed positively to the overall health of the cells.  In addition, 
it could be said that a given polymer type is more compatible than others when placed in 
the physiological environment. However, further testing to study the cell activity at the 
various time points was required. 
Although the results showed varying levels of LDH release, cytotoxicity levels 
had not reached a toxic range (i.e. > 30%) after 24 hours of exposure (Figure 5.17a).  For 
LDH activity over a 24-hour period, cytotoxicity levels were expected to increase slightly 
over time due to the natural death process.  However, at the end of the 24-hour period, the 
greatest difference existed between the cells only (i.e. low control) and the uncoated 
magnesium alloy cultures (Figure 5.17b).  This indicates that any apparent toxicity that 
was present in the cultures was unlikely due to the polymer coating materials.  These 
findings seem to be consistent with the results from the ICP tests in which it was 
concluded that there were no significant differences between polymer coating materials.  
However, an analysis of statistical significance for percentage LDH activity among the 
treatment types was necessary. 
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Figure 5.16 Depiction of fluctuating LDH activity for all time points 
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(a) 
 
(b) 
Figure 5.17 (a) Depiction of trends in LDH activity over 24 hours (b) increasing 
LDH activity over 24 hours  
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The experimental data were assessed to ensure the assumptions of normality and 
randomness were satisfied.  It was determined that the data were normally distributed and 
did not exhibit any obvious trends or patterns, thus the data was, in fact, random in 
nature.  A depiction of the normality and randomness plots for the LDH data set is shown 
in figure 5.18a and b, respectively.   As a result, the statistical relevance of the 
independent variables on percentage LDH activity after 24 hours was suitable for the 
application of analysis of Variance (i.e. ANOVA) statistical tests. 
A one-way analysis of variance was conducted on the percentages of LDH 
activity after a 24-hour period. The differences between the mean LDH release for each 
sample treatment type are depicted in figure 5.19.  The results showed that significant 
differences between at least one of the means for LDH release were present given p = 
0.041, amongst the experiment groups at p < 0.05 (Appendix D).  Therefore it was 
necessary to reject the null hypothesis that there were no significant differences between 
the means of the identified experiment groups.   
A follow-up post hoc analysis was performed to determine specific differences.  
Findings from the Tukey’s post hoc analysis showed that there were significant 
differences between the low control (cells only) samples and the uncoated samples.  It is 
important to note that the results of this analysis confirm also that the presence of 
magnesium does show that the LDH activity decreases significantly following 
magnesium exposure.  Differences between all other experiment groups were found to be 
insignificant.  Thus, these findings are consistent with the results from the immersion 
tests.   
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(a) 
 
(b) 
Figure 5.18 (a) Normality plot and (b) randomness plot for LDH data collection set  
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Figure 5.19 Box plot for LDH data depicting differences in data means 
 
The samples from the LDH release experiment were preserved so that the 
magnesium ion content of the sample media collected could also be measured. The 
experimental data were assessed to ensure the assumptions of normality and randomness 
were satisfied.  It was determined that the data were normally distributed and did not 
exhibit any obvious trends or patterns, thus the data was, in fact, random in nature.  The 
normality and randomness data plot for magnesium content in the LDH samples are 
shown in figures 5.20a and b, respectively.  As a result, the statistical relevance of the 
independent variables on magnesium ion content in the LDH samples was, again, suitable 
for the application of analysis of Variance (i.e. ANOVA) statistical testing. 
A one-way ANOVA was also conducted on the magnesium content present 
within the samples cell wells to determine if there was a difference of means between at 
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least two of the experiment groups.  The results of this analysis confirmed that there were 
highly significant differences given p = 0.005, between at least two of the groups at p < 
0.05 (Appendix D).   The differences between mean magnesium content for the LDH 
sample treatment types are depicted in figure 5.21.  Here again, the null hypothesis was 
rejected and Tukey’s post hoc analysis was conducted to determine specific differences.   
The results showed that the difference in means between the low control (cell 
only) and the uncoated samples was significant.  There was also a significant difference 
between the low control and the samples containing the PCL coating.  Lastly, statistical 
differences were found between the samples containing the PEUU coating and both the 
uncoated and PCL coated samples.  This is also consistent with the ICP results from the 
immersion test in which both the uncoated and PCL coated samples displayed similar 
corrosion behaviors.  Also, from the immersion test, the PEUU coated samples released 
the lowest magnesium ion content, which is shown here to be comparable to the low 
control.  Therefore, the statistical differences occur between the groups that were 
expected from the ICP results to have the highest and lowest magnesium content.  In the 
following section we conduct a PCR analysis to determine if whether the LDH release is 
a result of the polymer coating type or increases in magnesium content. 
Here again, these results confirm that although, PCL seems to offer the least 
protection from corrosion, the cells showed a positive reaction to the increased exposure 
to the magnesium.  This again indicates that controlled magnesium exposure promotes 
good health in airway cells.   
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(a) 
 
(b) 
Figure 5.20 (a) Normality plot and (b) randomness plot for LDH data  
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Figure 5.21 Box plot for LDH data depicting differences in data means  
5.3.3 PCR Analysis 
A polymerase chain reaction (PCR) analysis was performed to measure the Cox-2 
gene expression in NHBE cells exposed to different sample conditions. The Cox-2 gene 
expression is indicative of the inflammatory response of the cells. This analysis was an 
end point analysis that allowed us to understand the health of the cells at the end of 29 
hours.  The corrosion of magnesium alloy samples resulted in release of magnesium ions 
within the media. The presence of magnesium ions within the media was measured using 
the ICP analysis. Thus, depending on their presence, it was hypothesized that higher 
magnesium ions resulted in higher Cox-2 gene expression based on the cell distress.  
The PCR results for the different samples were labeled below as follows, 1-6 
PCL, 7-12 PLGA, 13-18 PEUU, 19-21 Uncoated, 22-23 Cells only. The PCR for both 
Beta Actin and COX-2 were analyzed where Beta Actin was used as an internal control. 
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The average intensity of 6 bands was used to normalize the Cox-2 data sets. Base pair 
150 was used to analyze intensity of Cox-2. The PCR image was inverted to measure 
darker intensities at base pair 150 for the different sample groups noted above. The 
darkness intensities were integrated to obtain volumetric intensities for further statistical 
analysis.   
 
Figure 5.22 Normalized Cox-2 gene expression 
 
The higher Cox-2 gene expression in both uncoated (bare) and PCL polymer 
coating, shown in Figure 5.22, is due to the corresponding higher presence of magnesium 
ions within the media. The PCL polymer coating resulted in the formation of pockets that 
entrap media leading to higher corrosion rates. The two polymers PLGA and PEUU 
offered higher protection to the underlying Mg alloy surface resulting in lower 
magnesium ion release and corresponding Cox-2 gene expression. The Cox-2 gene 
expression values for PEUU and PLGA are comparable to those of natural cells (low 
control). These results seemed to be consistent with the magnesium ion content within 
media for different sample types as explained previous sections.  However, test for 
statistical differences was necessary.   
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The experimental data were assessed to ensure the assumptions of normality and 
randomness were satisfied.  It was determined that the data were normally distributed and 
did not exhibit any obvious trends or patterns, thus the data was, in fact, random in 
nature.  As a result, the statistical relevance of the independent variables on Cox-2 gene 
expression was suitable for the application of analysis of Variance (i.e. ANOVA) 
statistical testing. 
A one-way ANOVA was conducted to test if significant differences existed 
among the different experiment types. Based on a p-value of 0.0266 from the results of 
the ANOVA it was concluded that significant differences exist for the Cox-2 gene 
expression. Thus, the null hypothesis was rejected.  Further, a Tukey’s post-hoc analysis 
was performed to identify significant differences between different sample types. As can 
be seen from Table 5.3, the uncoated (bare) sample and PCL polymer coating show 
statistically significant higher gene expression as compared the cells (low control). Also, 
PCL polymer exhibited statistically significant difference as compared to PEUU polymer.   
 Table 5.3 Tukey's post hoc analysis for Cox-2 gene expression 
 
From the results of the PCR analysis it was determined that the cell response 
exhibited through inflammation was due to the increase in magnesium ion content.    It 
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was also determined that the differences between polymer materials when compared 
amongst each other were insignificant and showed no negative influences on cell health.  
Lastly, when the desire is to decrease the rate of corrosion for magnesium alloys, PCL 
was not the best candidate as its performance was similar to the uncoated samples.  The 
PLGA and PEUU coatings offered better protective coatings.  
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CHAPTER 6 
CONCLUSIONS 
6.1 Overview 
The objective of this research was to apply a novel surface modification technique 
namely Direct-Write Inkjet printing, to develop functional coatings for metallic 
biomaterials.  Inkjet printing offers several advantages such as the capability to produce 
coatings on extremely complex structures, deposition onto the outer surfaces only, and 
flexibility to change coating design and materials.  This technique also allows for the 
adjustment of coating thickness with the objective of obtaining desired release patterns.   
6.2 Controlled Release Coatings  
Controlled release coatings are fabricated to suit a variety of different 
applications.  More specifically, the controlled release of various biological agents from 
biodegradable polymer coatings to treat a vast number of physiological ailments is of 
particular interest.  The use of the Direct Write inkjet technique as a mechanism for 
developing controlled release coatings offers a variety of advantages for coating surfaces 
containing biological and pharmaceutical reagents [48].  For instance, this technique uses 
a data driven pressure source for deposition of material onto a given substrate, where 
other fabrication techniques use electricity, which may compromise the integrity of the 
biological substances [48].  Other techniques such as spin coating and dip coating are not 
able to accommodate the complex structures that are usually required by surgical implant 
devices.  None of the deposition techniques discussed earlier offer the ability to deposit 
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target specific coatings, maintain the integrity of the deposition material, and eliminate 
cross-contamination of materials.   
The need for a coating technique that encompasses all of the benefits mentioned 
above is necessary to develop controlled release coating where spatial requirements can 
be specified to develop coatings with specified porosity and degradation features.  In this 
research, the intent was achieve a variety of drug release profiles that could be tailored to 
support the needs of a given drug delivery application.  Here, the drug concentration and 
layers of coating material were varied to assess coating specifications resulting in a 
steady state release throughout its intended time of function.  This result would be 
desirable for ailments requiring extended therapeutic sessions such as neointimal 
hyperplasia, using an anti proliferative such as Paclitaxel, following placement of a 
cardiovascular stent device [6].  Coatings having a more profound initial burst phase were 
also attempted.  These coatings would be more suitable for applications such as 
antimicrobial and/or antifibrotic therapy were the majority of the reagent is required in 
the initial stages of treatment to treat infection at the implant site and promote healthy 
wound healing [83-84]. 
The coating process required that various concentrations of the synthesized 
biopolymer fluids were tested to determine their “jettability”.  In this research, the term 
jettability was defined as being able to maintain a steady jet for a time period of at least 
2-3 hours.  Thus, a steady jet was achieved for non-newtonian fluids.  This process was 
known as the jetting optimization process.  In a preliminary study jetting optimization 
was attempted for PEUU at 2% w/v, 1.5% w/v, 1% w/v, and 0.5% w/v.  It was concluded 
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that the concentration for which a steady jet was obtained for PEUU was 0.5 % w/v.  The 
specific jetting parameters for this material were provided in Chapter 4.   
The non-contact, data-driven deposition process showed suitability for depositing 
drug-loaded polymer (Paclitaxel and PEUU) on to a titanium substrate simulating stent-
coating applications. The coatings types were varied in polymer and drug concentration 
and thickness to determine how manipulating the three would affect the drug release 
profile.  Preliminary studies revealed that drug release could be achieved for a period of 
35 days, which was comparable to release periods of using other notable coating 
techniques found in literature.  After 5 days, the samples with thicker coatings began to 
peel from the substrate and thus characterization release was not obtained after that time 
period.  The thinner coatings with lower drug concentrations showed a steady release 
pattern.  
Further studies were conducted in which the polymer concentration remained 
constant (0.5% w/v) and only the drug concentration and layer thickness were varied to 
determine their effect on the drug release profile as well as hemocompatibility and cell 
inhibition.  The titanium substrates underwent standard cleaning procedures to improve 
polymer surface adhesion.   
Drug release profiles were obtained for a 21-day period. A design of experiment 
(DOE) was used to determine the main and interaction affects of each factor on the total 
drug release as well as the percentage released during the burst release period.  Higher 
percentages of drug release during the burst phases were observed for the samples with 
thinner coatings and vice versa.  The overall drug concentrations observed at the end of 
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21 days where significantly lower for samples with lower drug loading.  In terms of the 
coating thickness, an increased coating layer generally showed higher final 
concentrations then samples coated with fewer layers. The P-values obtained from the 
DOE were highly significant (p < 0.01).   It was concluded that tunable drug release 
coatings could be fabricated to suit various therapeutic requirements.   
The reagent chosen, Paclitaxel, has been proven to inhibit accelerated cell 
proliferation in cancerous environments, thus biological testing was conducted to relate 
the drug release profiles to cell inhibition.  MTT assay was performed on rat smooth 
muscle cells after being cultured on the surfaces of taxol-loaded polymer coatings for 1, 
4, and 7 days.  Cells were also cultured on TCPS material, uncoated titanium, and 10 and 
20 layers of PEUU with no drug as controls.  A one-way ANOVA was performed to 
determine any significant differences within each of the experiment types and the 
controls.  Significant differences were determined for each of the experiment types as 
compared to the controls.   
Hemocompatibility test were also conducted to relate drug release to blood 
coagulation on the functionalized surfaces. Platelet deposition onto the sample surfaces 
was determined by LDH assay. The statistical significance between sample groups was 
determined using One-way Analysis of Variance (ANOVA) and post-hoc Newman-Keuls 
testing was performed to determine specific differences.  Statistical significance between 
the samples containing only PEUU (control) and both sets of samples containing 5% and 
10% taxol embedded in PEUU were observed.  However, although differences were 
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observed when increasing drug concentration from 5% w/v to 10% w/v, the effect on 
blood platelet deposition was found to be insignificant.   
6.3 Polymer Coatings for Controlling the Corrosion of Mg Alloys 
Biofunctional coatings are necessary to suit a variety of different medical 
applications. The use of the Direct Write inkjet technique as a mechanism for enhancing 
the structural integrity of a given biomaterial via biofunctional coatings, namely 
magnesium and its alloys, is of growing interest.  Uses for magnesium as a biomaterial 
offers several advantages and can spread across a number of applications.  For instance, 
magnesium is essential to over 300 physiological functions within the body [85] and has 
also been identified as a potential biomaterial to facilitate bone growth and repair due to 
proven similarities of mechanical strength with the cortical bone [86]. 
Direct Write deposition can be used to fabricate coatings where spatial 
requirements can be specified to develop coatings with specified porosity and 
degradation features for inhibiting the corrosion of magnesium alloys.  In this study, the 
intent was to investigate a variety of polymer coatings having various rates of 
degradation.  Here, the polymer type and layers of coating material were varied to assess 
coating specifications for applications in corrosion protection and controlled release of 
magnesium alloys.  Corrosion protection is essential to ensure that a polymer coating is 
applied, which can extend the life of the surgical device until its intended function is 
completed [86].  The controlled release of magnesium in the trachea can be beneficial in 
relaxing airway cells when exposed to an environment causing inflammation [87].  
Magnesium deficiencies have also been linked to cardiovascular disease.  Thus, 
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controlled release of magnesium via controlled release coatings can offer some benefit 
when applied to tracheal and cardiovascular stent devices [88]. 
The direct-write inkjet technique was used to develop polymer coatings that 
would aid in controlling corrosion of magnesium alloys for orthopedic and vascular 
applications.  It was hypothesized that by manipulating droplet sizes and pitch distance as 
well as polymer type and thickness, desirable corrosion rates based on a given application 
could be obtained.  The jetting optimization process was carried out to determine the 
highest printable concentration for both PCL and PLGA.  It was determined that both 
polymers could be printed at 1% w/v concentration (provided in Chapter 4).  The 
concentration for PEUU remained at 0.5% w/v.   
In a preliminary study, the direct-write printing process was utilized to deposit 
precise layers of multilayer polymeric coatings on Mg alloy surface (Mg: 90%, Zn: 8.9%, 
Ca: 0.5%, rest impurities). PLGA and PCL polymers coatings displayed distinct 
corrosion characteristics based on their varying degradation properties. The uncoated 
(bare) Mg alloy sample showed incremental weight gain and loss due to formation and 
release of Mg(OH)2 corrosion products, respectively. The coating types were classified 
based on polymer type (PCL and PLGA) and pitch distance (50 µm, 100 µm).  Coatings 
with larger deposition pitch (100µm) had higher porosity in both polymer types. This 
resulted in media infiltration and corrosion of local regions on the substrate. The 
corrosion behavior of PCL-50 and PLGA-50 was analogous, though PCL-50 showed 
slower corrosion rate. The PCL-100 film retained corrosion products due to better 
adhesion properties with the Mg substrate.  The results showed that by varying polymer 
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type and printing conditions one could adjust the corrosion rate of magnesium alloys for 
its intended uses.  Manipulation of the step and pitch sizes allowed for added control of 
coating degradation based on one of the given applications provided above.   
In a further study, the pitch distance remained constant (50 µm) to achieve more 
protective coatings with a third polymer type (PEUU).  Immersion testing was conducted 
to determine the affect of polymer type and coating thickness on the presence of 
magnesium released in simulated body fluid (SBF).  Uncoated samples were also tested 
as a control and sample aliquots were collected over an 8-day period.  Magnesium ion 
content was measured using inductively coupled plasma (ICP) spectroscopy technique.   
Statistical analysis was conducted to determine the main and interaction effects 
amongst the treated samples.  Though there were visible trends from the data, the 
differences of means amongst the coating types were not significant. A analysis was 
conducted to compare each experiment type against the control (uncoated). The results 
from this analysis showed that the difference in the data mean for the uncoated samples 
was statistically different from the mean samples coated with 20 passes of PEUU.  This 
suggests that PEUU with increased coated materials would be ideal for applications such 
as bone growth and repair where slower corrosion rates is required to match the rate of 
bone growth. 
The controlled release of magnesium in the trachea can be beneficial in relaxing 
airway cells when exposed to an environment causing inflammation [87].  Cell viability 
and surface interaction between NHBE (airway) cells and the magnesium alloy with 
various coating types were also investigated in culture.  LDH activity was assessed to 
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determine the effect of magnesium exposure from different samples on cytotoxicity. 
Although the results showed varying levels of LDH release for the coated samples, 
cytotoxicity levels were within permissible physiological limits (i.e. < 30%) after 24 
hours of exposure. ANOVA results concluded that there was a significant difference 
between the mean LDH release from cells containing uncoated magnesium samples and 
the cells having no magnesium exposure.  The analysis also revealed that, compared to 
the cells with no magnesium exposure, the cells exposed to magnesium showed increased 
health during the testing period.  This confirms that airway cells would benefit from the 
controlled release of magnesium to promote good health within the trachea.   
ICP analysis was conducted to evaluate the magnesium content present within 
samples. The low control (cell only) had statistically significant lower Mg ion presence as 
compared to the uncoated samples.  There was also a significant difference between the 
low control and the samples containing the PCL coating.  Statistical differences were 
found between the samples containing the PEUU coating and both the PCL and uncoated 
samples. 
From the results, it was determined that the PCL-coated samples produced 
equivalent magnesium content in SBF when compared to uncoated.  Thus, the PCL 
polymer is not an ideal polymer material if the intent is to retard the corrosion process.  
The magnesium content observed in the sample media from the PEUU-coated 
magnesium was similar to the amount observed from the low control (cells only).  PLGA 
offered slightly lower protection than the PEUU.  Because the PCL coating was similar to 
that of the uncoated sample and PEUU was similar to the low control, significant 
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differences were found between PEUU and PCL.  These findings were also consistent 
with the results from the immersion and LDH tests thus, validating the relationship 
between magnesium exposure and cell health. 
A polymerase chain reaction (PCR) analysis was performed to measure the Cox-2 
gene expression in NHBE cells exposed to different sample conditions. The Cox-2 gene 
expression is indicative of the inflammatory response of the cells exposed to the various 
polymer-coating types. Higher Cox-2 gene expression was found in both the uncoated 
and PCL polymer coated which was consistent with the findings from the previous 
experiments.  This suggests that after 29 hours of continuous exposure to high levels of 
magnesium, percentage of LDH began to approach the level of acceptability (i.e. 30%).  
The results also revealed that the PEUU and PLGA polymer coating material seemed to 
be the most biocompatible, as the Cox-2 gene expression for those samples were most 
similar to that of the cells alone.   
In conclusion, there is sufficient evidence to state that the inflammatory response 
of the cells is proportional to the increasing magnesium exposure.   If the intent is to 
control the corrosion rate of magnesium alloys for a given application, PCL can be 
excluded as a potential candidate for coating as it corrodes at similar rates as the 
magnesium alloy with no coating.  PEUU and PLGA polymers may be considered for 
further testing as the showed good biocompatibility and corrosion control. Therefore, this 
research establishes a foundation for determining the best candidate polymer material for 
controlling the corrosion of magnesium alloys as they apply to numerous applications for 
controlled degradation of biomaterials for surgical implant devices.   
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6.4 Future Work 
6.4.1 Controlled Release Coating 
• New polymeric materials should be incorporated as possible candidate to 
achieve desired drug release profiles. 
• Biphasic and bio-triphasic drug delivery coatings should be developed to 
achieve a desired therapeutic effect. 
6.4.2 Polymer Coatings for Corrosion Retardation 
• Further biological testing should be conducted regarding cell response to 
polymer-coated magnesium. 
• Chemical properties of a given polymer type should be adjusted to inhibit 
the corrosion process, namely PLGA. 
• Biphasic and bio-triphasic drug delivery coatings should be incorporated 
to enhance the surface of the magnesium substrate. 
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APPENDIX A 
CONTROLLED RELEASE COATINGS 
Full Factorial Design for Burst Release 
 
Factors:  2   Base Design:         2, 4 
Runs:     8   Replicates:             2 
Blocks:   1   Center pts (total):     0 
 
 
All terms are free from aliasing. 
 
 
Design Table (randomized) 
 
Run  A  B 
  1  -  + 
  2  +  - 
  3  +  + 
  4  +  - 
  5  -  + 
  6  -  - 
  7  -  - 
  8  +  + 
 
 
 
  
Factorial Fit: Burst Release versus %Taxol Con., No. of passes  
 
Estimated Effects and Coefficients for Burst Release (coded units) 
 
Term                        Effect     Coef   SE Coef       T      P 
Constant                            0.60569  0.005898  102.69  0.000 
%Taxol Con.                0.42379  0.21190  0.005898   35.93  0.000 
No. of passes              0.13340  0.06670  0.005898   11.31  0.000 
%Taxol Con.*No. of passes  0.19379  0.09690  0.005898   16.43  0.000 
 
 
S = 0.0166827   R-Sq = 99.76%   R-Sq(adj) = 99.59% 
 
 
Analysis of Variance for Burst Release (coded units) 
 
Source              DF    Seq SS    Adj SS    Adj MS       F      P 
Main Effects         2  0.394790  0.394790  0.197395  709.26  0.000 
2-Way Interactions   1  0.075111  0.075111  0.075111  269.88  0.000 
Residual Error       4  0.001113  0.001113  0.000278 
  Pure Error         4  0.001113  0.001113  0.000278 
Total                7  0.471014 
 
 
Estimated Coefficients for Burst Release using data in uncoded units 
 
Term                             Coef 
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Constant                     0.641970 
%Taxol Con.                -0.0315170 
No. of passes              -0.0447980 
%Taxol Con.*No. of passes  0.00775170 
 
 
Least Squares Means for Burst Release 
 
                             Mean   SE Mean 
%Taxol Con. 
  5                        0.3938  0.008341 
 10                        0.8176  0.008341 
No. of passes 
 10                        0.5390  0.008341 
 20                        0.6724  0.008341 
%Taxol Con.*No. of passes 
  5 10                     0.4240  0.011796 
 10 10                     0.6540  0.011796 
  5 20                     0.3636  0.011796 
 10 20                     0.9812  0.011796 
 
 
Alias Structure 
I 
%Taxol Con. 
No. of passes 
%Taxol Con.*No. of passes 
 
Total Release DOE 
 
Factorial Fit: Total Release versus %Taxol Con., No. of passes  
 
Estimated Effects and Coefficients for Total Release (coded units) 
 
Term                       Effect   Coef  SE Coef       T      P 
Constant                           59.14   0.3650  162.04  0.000 
%Taxol Con.                 49.72  24.86   0.3650   68.11  0.000 
No. of passes               33.81  16.91   0.3650   46.32  0.000 
%Taxol Con.*No. of passes   20.01  10.00   0.3650   27.41  0.000 
 
 
S = 1.03233   R-Sq = 99.95%   R-Sq(adj) = 99.91% 
 
 
Analysis of Variance for Total Release (coded units) 
 
Source              DF   Seq SS   Adj SS   Adj MS        F      P 
Main Effects         2  7230.07  7230.07  3615.04  3392.17  0.000 
2-Way Interactions   1   800.40   800.40   800.40   751.06  0.000 
Residual Error       4     4.26     4.26     1.07 
  Pure Error         4     4.26     4.26     1.07 
Total                7  8034.73 
 
 
Estimated Coefficients for Total Release using data in uncoded units 
 
Term                           Coef 
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Constant                    23.8700 
%Taxol Con.                -2.06000 
No. of passes              -2.62000 
%Taxol Con.*No. of passes  0.800200 
 
 
Least Squares Means for Total Release 
 
                             Mean  SE Mean 
%Taxol Con. 
  5                         34.29   0.5162 
 10                         84.00   0.5162 
No. of passes 
 10                         42.24   0.5162 
 20                         76.05   0.5162 
%Taxol Con.*No. of passes 
  5 10                      27.38   0.7300 
 10 10                      57.09   0.7300 
  5 20                      41.19   0.7300 
 10 20                     110.91   0.7300 
 
 
Alias Structure 
I 
%Taxol Con. 
No. of passes 
%Taxol Con.*No. of passes 
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APPENDIX B 
POLYMER COATINGS FOR COROSION RETARDATION: A PILOT STUDY 
 
Overview 
 Appendix B details the preliminary experiment procedure for cell culture and 
surface-cell interactions experiments.  The experimental results and statistical analysis 
from this preliminary test are also presented here.   
Cell Culture Procedure 
 Normal Human Bronchial Epithelial (NHBE) cells were cultured in complete 
media, which consisted of a 50:50 mixture of BEBM/DMEM supplemented with 
antibiotics and growth factors.  The cells were rapidly thawed from liquid nitrogen in a 
37oC water bath and seeded in 6-well culture dishes fitted with rat tail collagen-coated 
polycarbonate membrane Transwell® inserts (0.4 µm pore).  Complete media (500 mL) 
was prepared by combining 250 mL of BEBM and 250 mL of DMEM into a flask with 
SingleQuot® components.  The cells were fed apically and basolaterally every other day 
until they reached 100% confluency (at approximately 7 days).  At that point, an air 
liquid interphase (ALI) was established by removing medium from the apical chamber 
and cells were fed basolaterally everyday for 14 days to allow full differentiation of the 
airway epithelial phenotype.  .  The cells were cultured at 37°Celcius in humidified air 
and 5% CO2. 
 Cell – Surface Interface Testing Procedure 
 The 10X10 mm Mg samples (n=3 per coating) were coated with 20 layers of 
polymer and sterilized under a laminar flow hood with a UV sterilization bulb for 15 
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minutes on each side.  Due to apparent differences in cells across the wells, the wells, 
which looked the healthiest, were chosen for the experiment.  Each of the samples were  
assigned a well number were they were placed face down such that the coated 
magnesium surface was in direct contact with the epithelial cell layer.  The wells were 
labeled as the low control, thus they were cells, which were untreated.  Initial media 
samples were collected from each well at time zero and stored at -20oC until need for 
lactate dehydrogenase (LDH) and or elemental analysis via inductively coupled plasma 
mass spectrometry (ICP-MS).    Fresh medium was placed in the lower chamber of each 
well and the plates were placed in incubation at 37°C and 5% CO2.   
Balolateral medium samples were collected again at 1 hour, 4, hours, 6 hours, 24 
hours, and 48 hours.  During the sample collection period, 1.5 mL of the sample media 
was collected from each of the wells and placed into a small tube.  The tubes were 
labeled and frozen at -20°C.  Any remaining media was aspirated from the cell well and 
two mL of fresh media was reapplied to the lower chamber.  During this period, selected 
wells were imaged by phase contrast microscopy using an Evos xl inverted  microscope 
(AMG).  After the final sample collection, the wells containing the untreated cells were 
lysed such that all LDH activity would be released.  These samples were then labeled as 
the high control and used for LDH analysis.   
LDH Assay 
Following exposure to coated Mg samples, reactions were terminated by 
removing materials from the apical surface, collection of basolateral culture medium and 
plates were wrapped in foil and stored at -80o C until needed for gene expression analysis.  
167  
The Roche cytotoxicity detection kit was used to determine LDH release by the cells at 
the indicated time points.  The low control consisted of the untreated cells (n=3) and the 
high control consisted of the lysed cells, which provided information about the maximum 
amount of released LDH activity in the cells.  The assay was performed according to 
manufacture’s recommendation and samples (in triplicate) were transferred into a 96-well 
plate according to the template found below.  
 Table A.1 96-well template for preliminary LDH data collection 
  
 Absorbance measurements were taken for each time point at 492 nm on a 
VersaMAX microplate reader (Molecular Devices).  To determine the percentage 
cytotoxicity, the average of the triplicates were obtained and the cytotoxicity percentage 
was calculated using equation.  Where, exp. is the experimental value obtained from the 
absorbance readings, low control is the absorbance value obtained from cells with no 
magnesium exposure, and high control is the absorbance value obtained from samples 
containing the maximum LDH activity.   
 
Experimental Design  
The purpose of this experiment was to gauge the effects of polymer coating 
material on the percentage of LDH activity from the cultured cells. The various 
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conditions identified for comparison were untreated magnesium alloys, samples coated 
with PCL, PLGA, and PEUU.  A low control that consisted of cultured cells with no 
magnesium exposure.  Having this low control would allow us to compare the 
magnesium containing samples to the natural cell death process.  A one-way analysis of 
variance was chosen to determine the statistical differences between the means of the 
various experiment groups. 
The question was posed, “Can direct-write inkjet printing be used as a mechanism 
for depositing uniformly distributed protective thin films?”  Furthermore, “Can these thin 
films aid in retardation of the corrodible AZ31 magnesium alloy in physiological 
solutions?”  More specifically, we seek to answer the following questions: 
1. Does polymer type and coating thickness have a significant effect on the rate of 
metal ion release? (Phase 1) 
2. Does polymer coating type have a significant effect on the percentage of LDH 
activity from Human Bronchial Epithelial Cells? (Phase 2) 
Results 
 Preliminary cell culture testing was conducted to determine the effects of polymer 
coating type on the percentage of LDH activity and magnesium presence in sample media 
at various time points. LDH activity was collected over a course of a 48 hour period at t = 
0, 1, 4, 6, 24 and 48 hours.  The sample data collected at time zero represents two distinct 
events.  The first is that this sample was collected at the end of a 24-hour feeding during 
which some LDH activity had already occurred.  This is apparent in the graph shown 
below which depicts a sample reading that shows significantly higher LDH activity when 
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compared to subsequent readings.  Also, at time zero fresh media was added to each of 
the sample wells to initiate the new testing period.  Thus, it is taken that each time point 
represents the end of a sample collection period. 
 The samples collected at each time period were evaluated as percentages of the 
high control, that is, the total amount of LDH that could be released from the cells.  
Given that the samples collected at time zero contained 24 hours worth of LDH activity 
before magnesium exposure, this provided some indication of the cell health before the 
experiment was started.   The sample data collected at time zero indicates that the cell 
health of the wells that were chosen as the low control was significantly lower than the 
wells assigned to the other experiment groups due to a high percentage of LDH release.   
 Sample media collected between t = 1 and t = 6 hours showed very little LDH 
release occurred and that activity was fairly consistent between the experiment groups.  
Between t = 6 and t = 24 hours a slight jump in percentage LDH activity is realized with 
PEUU coated samples having the highest activity and uncoated samples showing the 
least.  Finally, at t = 48 hours the data shows a great increase in all of the experiment 
groups, however it remains that the PEUU show the highest release percentage where the 
uncoated samples continue to show the least.  The results indicated that the cells are able 
to maintain good health as they are exposed to the magnesium.  However the cells seem 
to react more to the polymer coatings, specifically, PEUU.   
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Figure A.1 Depiction of fluctuating LDH for all time points of preliminary study 
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(a) 
 (b) 
Figure A.2 (a) Depiction of trends in LDH activity over 24 hours (b) increasing LDH 
activity over 24 hours for preliminary data set 
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 A one-way analysis of variance (ANOVA) was conducted to determine if there 
are significant differences between the means of the experiment groups.  The results 
showed that significant differences do exist between at least two of the sample types (p < 
0.05).  Therefore, the null hypothesis stating that there are no differences between the 
means was rejected and further analysis was required.  Tukey’s analysis was conducted to 
determine specific differences between groups.  Here results showed that statistical 
differences occurred between the low control (cells only) and the uncoated samples.  The 
differences amongst all other sample types were shown to be insignificant.   
 
Figure A.3 Depiction of differences in LDH for preliminary data set 
 Samples from each experiment group were also collected for inductively coupled 
plasma (ICP) analysis.  The ICP analysis was to determine whether or not the various 
treatment types affected magnesium presences within the collected samples.  The data 
shows higher magnesium presences from PCL-coated samples and lower magnesium 
presence for PEUU-coated samples.  A one-way ANOVA was performed on the data, 
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which revealed that the differences in means for magnesium presences were not 
significant thus; the results here were likely due to chance and possibly variations in the 
sample types.  Overall, it seemed that cells may be reacting to the polymer type as oppose 
to magnesium exposure.   
 
Figure A.4 Magnesium presence in LDH samples for preliminary data set 
 
Figure A.5 Depiction of mean differences in mg content for preliminary data 
Conclusions 
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 Normal Human Bronchial Epithelial cells were culture in Air-Liquid Interface.  
Magnesium samples set in epoxy resin material were coated using direct-write 
techniques.  Cell wells were selected bases on apparent cell health at the start of the 
experiment and randomly assigned to an experiment group.  The samples were placed for 
surface interaction between the cells and polymer coated magnesium surfaces in which 
the samples were tested for percentage of LDH activity and magnesium presence in the 
sample fluid.    
Statistical analysis (ANOVA) was conducted on the results for a 48-hour period, 
which determined that there were no significant differences in the polymer coating types 
on the percentage of LDH activity.  However the difference in means between the cells 
and the uncoated samples was significant indication a positive reaction to the magnesium 
from the uncoated samples.  It is also evident from the results of the test that declining 
cell health could be a response to the biocompatibility of the polymer types rather than 
increased magnesium exposure.   
In conclusion, this test should be conducted again with cells having similar health 
at the start of the experiment.  Also smaller samples sizes should be used to eliminate the 
possibility of weight contributing to accelerated cell stress.   
Statistical Analysis for Preliminary Experiments 
LDH shows statistical significance for NOV 
 
One-way ANOVA: Nov LDH  
 
Source   DF      SS     MS     F      P 
NOV_L24   4   869.7  217.4  4.31  0.028 
Error    10   504.9   50.5 
Total    14  1374.6 
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S = 7.106   R-Sq = 63.27%   R-Sq(adj) = 48.58% 
 
 
                          Individual 95% CIs For Mean Based on 
                          Pooled StDev 
Level  N    Mean   StDev  -+---------+---------+---------+-------- 
Bare   3  27.916   1.765  (--------*--------) 
Cells  3  47.403   8.556                     (--------*---------) 
PCL    3  29.004   7.374   (--------*--------) 
PEUU   3  38.709  10.630             (--------*--------) 
PLGA   3  28.822   2.958   (--------*--------) 
                          -+---------+---------+---------+-------- 
                          20        30        40        50 
 
Pooled StDev = 7.106 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of NOV_L24 
 
Individual confidence level = 99.18% 
 
 
NOV_L24 = Bare subtracted from: 
 
NOV_L24    Lower  Center   Upper  ---------+---------+---------+---------+ 
Cells      0.411  19.487  38.563                     (---------*--------) 
PCL      -17.988   1.088  20.164            (---------*--------) 
PEUU      -8.283  10.793  29.870                 (--------*---------) 
PLGA     -18.169   0.907  19.983            (--------*---------) 
                                  ---------+---------+---------+---------+ 
                                         -20         0        20        40 
 
 
NOV_L24 = Cells subtracted from: 
 
NOV_L24    Lower   Center   Upper  ---------+---------+---------+---------+ 
PCL      -37.475  -18.399   0.677  (---------*--------) 
PEUU     -27.770   -8.694  10.382       (---------*--------) 
PLGA     -37.657  -18.581   0.495  (---------*--------) 
                                   ---------+---------+---------+---------+ 
                                          -20         0        20        40 
 
 
NOV_L24 = PCL subtracted from: 
 
NOV_L24    Lower  Center   Upper  ---------+---------+---------+---------+ 
PEUU      -9.371   9.705  28.781                (---------*--------) 
PLGA     -19.258  -0.182  18.894           (---------*--------) 
                                  ---------+---------+---------+---------+ 
                                         -20         0        20        40 
 
 
NOV_L24 = PEUU subtracted from: 
 
NOV_L24    Lower  Center  Upper  ---------+---------+---------+---------+ 
PLGA     -28.963  -9.887  9.189       (--------*---------) 
                                 ---------+---------+---------+---------+ 
                                        -20         0        20        40 
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NOV ICP Data does not show statistical significance 
 
One-way ANOVA: Nov ICP NHBE  
 
Source     DF         SS         MS     F      P 
Nov18_T24   4  0.0000000  0.0000000  1.12  0.400 
Error      10  0.0000000  0.0000000 
Total      14  0.0000000 
 
S = 0.00005312   R-Sq = 30.93%   R-Sq(adj) = 3.30% 
 
 
 
Level  N        Mean       StDev 
Bare   3  0.00018672  0.00000492 
Cells  3  0.00014152  0.00000460 
PCL    3  0.00023239  0.00009136 
PEUU   3  0.00017941  0.00005646 
PLGA   3  0.00017791  0.00005027 
 
       Individual 95% CIs For Mean Based on Pooled StDev 
Level  --------+---------+---------+---------+- 
Bare           (----------*-----------) 
Cells  (-----------*----------) 
PCL                   (-----------*----------) 
PEUU          (----------*----------) 
PLGA         (-----------*----------) 
       --------+---------+---------+---------+- 
             0.000120  0.000180  0.000240  0.000300 
 
Pooled StDev = 0.00005312 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of Nov18_T24 
 
Individual confidence level = 99.18% 
 
 
Nov18_T24 = Bare subtracted from: 
 
Nov18_T24        Lower       Center       Upper 
Cells      -0.00018780  -0.00004520  0.00009741 
PCL        -0.00009693   0.00004567  0.00018828 
PEUU       -0.00014991  -0.00000730  0.00013530 
PLGA       -0.00015141  -0.00000880  0.00013380 
 
Nov18_T24  ---------+---------+---------+---------+ 
Cells         (-----------*-----------) 
PCL                   (-----------*-----------) 
PEUU              (----------*-----------) 
PLGA             (-----------*-----------) 
           ---------+---------+---------+---------+ 
                 -0.00012   0.00000   0.00012   0.00024 
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Nov18_T24 = Cells subtracted from: 
 
Nov18_T24        Lower      Center       Upper 
PCL        -0.00005173  0.00009087  0.00023348 
PEUU       -0.00010471  0.00003789  0.00018050 
PLGA       -0.00010621  0.00003640  0.00017900 
 
Nov18_T24  ---------+---------+---------+---------+ 
PCL                       (-----------*----------) 
PEUU                 (-----------*-----------) 
PLGA                 (-----------*-----------) 
           ---------+---------+---------+---------+ 
                 -0.00012   0.00000   0.00012   0.00024 
 
 
Nov18_T24 = PCL subtracted from: 
 
Nov18_T24        Lower       Center       Upper 
PEUU       -0.00019558  -0.00005298  0.00008963 
PLGA       -0.00019708  -0.00005448  0.00008813 
 
Nov18_T24  ---------+---------+---------+---------+ 
PEUU          (-----------*----------) 
PLGA          (----------*-----------) 
           ---------+---------+---------+---------+ 
                 -0.00012   0.00000   0.00012   0.00024 
 
 
Nov18_T24 = PEUU subtracted from: 
 
Nov18_T24        Lower       Center       Upper 
PLGA       -0.00014410  -0.00000150  0.00014111 
 
Nov18_T24  ---------+---------+---------+---------+ 
PLGA              (-----------*-----------) 
           ---------+---------+---------+---------+ 
                 -0.00012   0.00000   0.00012   0.00024 
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APPENDIX C 
Statistical Output for Magnesium Ion Content from Immersion Testing 
 
 
DOE ICP Mg –Immersion Test 
 
Multilevel Factorial Design  
 
Factors:      2     Replicates:     2 
Base runs:    6     Total runs:    12 
Base blocks:  1     Total blocks:   1 
 
Number of levels: 3, 2 
 
 
Design Table (randomized) 
 
Run  Blk  A  B 
  1    1  3  1 
  2    1  3  2 
  3    1  2  1 
  4    1  1  1 
  5    1  2  1 
  6    1  3  2 
  7    1  1  2 
  8    1  3  1 
  9    1  1  2 
 10    1  2  2 
 11    1  2  2 
 12    1  1  1 
 
  
General Linear Model: Mg-Immer versus Polymer Type, No. of Layers  
 
Factor         Type   Levels  Values 
Polymer Type   fixed       3  PCL, PLGA, PEUU 
No. of Layers  fixed       2  10, 20 
 
 
Analysis of Variance for Mg-Immer, using Adjusted SS for Tests 
 
Source                      DF     Seq SS     Adj SS     Adj MS     F      P 
Polymer Type                 2  0.0000114  0.0000114  0.0000057  2.15  0.198 
No. of Layers                1  0.0000002  0.0000002  0.0000002  0.09  0.770 
Polymer Type*No. of Layers   2  0.0000197  0.0000197  0.0000099  3.74  0.088 
Error                        6  0.0000159  0.0000159  0.0000026 
Total                       11  0.0000472 
 
 
S = 0.00162534   R-Sq = 66.41%   R-Sq(adj) = 38.43% 
 
 
Term                            Coef   SE Coef      T      P 
Constant                    0.002990  0.000469   6.37  0.001 
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Polymer Type 
PCL                         0.001277  0.000664   1.92  0.103 
PLGA                       -0.000195  0.000664  -0.29  0.778 
No. of Layer 
10                          0.000144  0.000469   0.31  0.770 
Polymer Type*No. of Layer 
PCL          10            -0.001804  0.000664  -2.72  0.035 
PLGA         10             0.001062  0.000664   1.60  0.161 
 
 
Least Squares Means for Mg-Immer 
 
Polymer Type                   Mean   SE Mean 
PCL                        0.004267  0.000813 
PLGA                       0.002794  0.000813 
PEUU                       0.001908  0.000813 
No. of Layer 
10                         0.003133  0.000664 
20                         0.002846  0.000664 
Polymer Type*No. of Layer 
PCL          10            0.002606  0.001149 
PCL          20            0.005927  0.001149 
PLGA         10            0.003999  0.001149 
PLGA         20            0.001589  0.001149 
PEUU         10            0.002794  0.001149 
PEUU         20            0.001021  0.001149 
 
 
ANOVA ICP Mg – Immersion Test 
 
One-way ANOVA: Mg-Imm versus Immer  
 
Source  DF         SS                  MS             F        P 
Immer    6  0.0000714  0.0000119  4.45  0.036 
Error       7  0.0000187  0.0000027 
Total      13  0.0000901 
 
S = 0.001635   R-Sq = 79.23%   R-Sq(adj) = 61.42% 
 
 
                               Individual 95% CIs For Mean Based on 
                               Pooled StDev 
Level   N      Mean     StDev  -----+---------+---------+---------+---- 
Bare    2  0.007821  0.001690                      (------*-------) 
PCL10   2  0.002606  0.000318       (------*-------) 
PCL20   2  0.005927  0.003085                (-------*-------) 
PEUU10  2  0.002794  0.000011       (-------*-------) 
PEUU20  2  0.001021  0.000213  (-------*-------) 
PLGA10  2  0.003999  0.002483           (------*-------) 
PLGA20  2  0.001589  0.000157    (-------*------) 
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                               -----+---------+---------+---------+---- 
                                  0.0000    0.0035    0.0070    0.0105 
 
Pooled StDev = 0.001635 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of Immer 
 
Individual confidence level = 99.46% 
 
 
Immer = Bare subtracted from: 
 
Immer       Lower     Center      Upper 
PCL10   -0.011699  -0.005214   0.001271 
PCL20   -0.008378  -0.001893   0.004592 
PEUU10  -0.011511  -0.005026   0.001459 
PEUU20  -0.013284  -0.006799  -0.000314 
PLGA10  -0.010306  -0.003821   0.002664 
PLGA20  -0.012717  -0.006232   0.000253 
 
Immer   ---------+---------+---------+---------+ 
PCL10     (---------*--------) 
PCL20          (--------*---------) 
PEUU10     (--------*--------) 
PEUU20  (--------*---------) 
PLGA10      (---------*--------) 
PLGA20   (--------*--------) 
        ---------+---------+---------+---------+ 
              -0.0070    0.0000    0.0070    0.0140 
 
 
Immer = PCL10 subtracted from: 
 
Immer       Lower     Center     Upper 
PCL20   -0.003164   0.003321  0.009806 
PEUU10  -0.006297   0.000188  0.006673 
PEUU20  -0.008070  -0.001585  0.004900 
PLGA10  -0.005092   0.001393  0.007878 
PLGA20  -0.007503  -0.001017  0.005468 
 
Immer   ---------+---------+---------+---------+ 
PCL20                 (---------*--------) 
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PEUU10            (--------*---------) 
PEUU20         (---------*--------) 
PLGA10              (--------*--------) 
PLGA20          (---------*--------) 
        ---------+---------+---------+---------+ 
              -0.0070    0.0000    0.0070    0.0140 
 
 
Immer = PCL20 subtracted from: 
 
Immer       Lower     Center     Upper 
PEUU10  -0.009618  -0.003133  0.003352 
PEUU20  -0.011391  -0.004906  0.001579 
PLGA10  -0.008413  -0.001928  0.004557 
PLGA20  -0.010824  -0.004339  0.002146 
 
Immer   ---------+---------+---------+---------+ 
PEUU10       (---------*--------) 
PEUU20     (--------*--------) 
PLGA10         (--------*---------) 
PLGA20      (--------*--------) 
        ---------+---------+---------+---------+ 
              -0.0070    0.0000    0.0070    0.0140 
 
 
Immer = PEUU10 subtracted from: 
 
Immer       Lower     Center     Upper 
PEUU20  -0.008258  -0.001773  0.004712 
PLGA10  -0.005280   0.001205  0.007690 
PLGA20  -0.007690  -0.001205  0.005280 
 
Immer   ---------+---------+---------+---------+ 
PEUU20         (--------*---------) 
PLGA10             (---------*--------) 
PLGA20          (--------*---------) 
        ---------+---------+---------+---------+ 
              -0.0070    0.0000    0.0070    0.0140 
 
 
Immer = PEUU20 subtracted from: 
 
Immer       Lower    Center     Upper 
PLGA10  -0.003507  0.002978  0.009463 
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PLGA20  -0.005917  0.000568  0.007053 
 
Immer   ---------+---------+---------+---------+ 
PLGA10                (--------*---------) 
PLGA20             (--------*--------) 
        ---------+---------+---------+---------+ 
              -0.0070    0.0000    0.0070    0.0140 
 
 
Immer = PLGA10 subtracted from: 
 
Immer       Lower     Center     Upper 
PLGA20  -0.008896  -0.002411  0.004074 
 
Immer   ---------+---------+---------+---------+ 
PLGA20        (---------*--------) 
        ---------+---------+---------+---------+ 
              -0.0070    0.0000    0.0070    0.0140 
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APPENDIX D 
STATISTICAL OUTPUT FOR FINAL LDH ACTIVITY AND MG CONTENT IN 
CULTURE MEDIA  
 
 
LDH shows statistical significance for DEC 
 
One-way ANOVA: LDH-T24_DEC  
 
Source   DF      SS     MS     F      P 
DEC_L24   4   848.0  212.0  3.75  0.041 
Error    10   564.7   56.5 
Total    14  1412.6 
 
S = 7.514   R-Sq = 60.03%   R-Sq(adj) = 44.04% 
 
 
                          Individual 95% CIs For Mean Based on 
                          Pooled StDev 
Level  N    Mean   StDev  -----+---------+---------+---------+---- 
Bare   3  28.080   4.594  (-------*-------) 
Cells  3  49.908  15.981                     (-------*-------) 
PCL    3  32.357   1.779      (-------*-------) 
PEUU   3  37.302   0.449          (-------*-------) 
PLGA   3  32.604   1.575      (-------*-------) 
                          -----+---------+---------+---------+---- 
                              24        36        48        60 
 
Pooled StDev = 7.514 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of DEC_L24 
 
Individual confidence level = 99.18% 
 
 
DEC_L24 = Bare subtracted from: 
 
DEC_L24    Lower  Center   Upper  ---------+---------+---------+---------+ 
Cells      1.655  21.829  42.002                      (---------*---------) 
PCL      -15.896   4.277  24.451             (---------*---------) 
PEUU     -10.951   9.222  29.396                (---------*---------) 
PLGA     -15.650   4.524  24.698             (---------*---------) 
                                  ---------+---------+---------+---------+ 
                                         -20         0        20        40 
 
 
DEC_L24 = Cells subtracted from: 
 
DEC_L24    Lower   Center  Upper  ---------+---------+---------+---------+ 
PCL      -37.725  -17.551  2.622  (---------*---------) 
PEUU     -32.780  -12.606  7.568     (---------*---------) 
PLGA     -37.478  -17.305  2.869  (---------*---------) 
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                                  ---------+---------+---------+---------+ 
                                         -20         0        20        40 
 
 
DEC_L24 = PCL subtracted from: 
 
DEC_L24    Lower  Center   Upper  ---------+---------+---------+---------+ 
PEUU     -15.229   4.945  25.119             (---------*----------) 
PLGA     -19.927   0.247  20.420           (---------*---------) 
                                  ---------+---------+---------+---------+ 
                                         -20         0        20        40 
 
 
DEC_L24 = PEUU subtracted from: 
 
DEC_L24    Lower  Center   Upper  ---------+---------+---------+---------+ 
PLGA     -24.872  -4.698  15.475         (---------*---------) 
                                  ---------+---------+---------+---------+ 
                                         -20         0        20        40 
 
DEC ICP Data shows statistical significance 
 
One-way ANOVA: Dec Mg ICP for NHBE  
 
Source     DF         SS         MS     F      P 
Dec16_T24   4  0.0000000  0.0000000  7.56  0.005 
Error      10  0.0000000  0.0000000 
Total      14  0.0000000 
 
S = 0.000006802   R-Sq = 75.16%   R-Sq(adj) = 65.22% 
 
 
                                  Individual 95% CIs For Mean Based on 
                                  Pooled StDev 
Level  N        Mean       StDev  ----+---------+---------+---------+----- 
Bare   3  0.00016682  0.00000595                        (--------*--------) 
Cells  3  0.00014512  0.00000765  (--------*--------) 
PCL    3  0.00016616  0.00000375                       (--------*--------) 
PEUU   3  0.00014572  0.00000655   (--------*-------) 
PLGA   3  0.00015067  0.00000897        (--------*-------) 
                                  ----+---------+---------+---------+----- 
                                    0.000140  0.000150  0.000160  0.000170 
 
Pooled StDev = 0.00000680 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of Dec16_T24 
 
Individual confidence level = 99.18% 
 
 
Dec16_T24 = Bare subtracted from: 
 
Dec16_T24         Lower        Center         Upper 
Cells      -3.99556E-05  -2.16933E-05  -3.43106E-06 
PCL        -1.89136E-05  -6.51333E-07   0.000017611 
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PEUU       -3.93596E-05  -2.10973E-05  -2.83506E-06 
PLGA       -3.44056E-05  -1.61433E-05   0.000002119 
 
Dec16_T24    +---------+---------+---------+--------- 
Cells        (--------*--------) 
PCL                     (--------*--------) 
PEUU         (--------*---------) 
PLGA            (--------*--------) 
             +---------+---------+---------+--------- 
           -4.0E-05  -2.0E-05  0.000000  0.000020 
 
 
Dec16_T24 = Cells subtracted from: 
 
Dec16_T24         Lower       Center        Upper 
PCL         0.000002780  0.000021042  0.000039304 
PEUU       -1.76663E-05  0.000000596  0.000018858 
PLGA       -1.27123E-05  0.000005550  0.000023812 
 
Dec16_T24    +---------+---------+---------+--------- 
PCL                               (---------*--------) 
PEUU                    (--------*--------) 
PLGA                       (--------*--------) 
             +---------+---------+---------+--------- 
           -4.0E-05  -2.0E-05  0.000000  0.000020 
 
 
Dec16_T24 = PCL subtracted from: 
 
Dec16_T24         Lower        Center         Upper 
PEUU       -3.87083E-05  -2.04460E-05  -2.18373E-06 
PLGA       -3.37543E-05  -1.54920E-05   0.000002770 
 
Dec16_T24    +---------+---------+---------+--------- 
PEUU          (--------*--------) 
PLGA            (--------*--------) 
             +---------+---------+---------+--------- 
           -4.0E-05  -2.0E-05  0.000000  0.000020 
 
 
Dec16_T24 = PEUU subtracted from: 
 
Dec16_T24         Lower       Center        Upper 
PLGA       -1.33083E-05  0.000004954  0.000023216 
 
Dec16_T24    +---------+---------+---------+--------- 
PLGA                      (--------*---------) 
             +---------+---------+---------+--------- 
           -4.0E-05  -2.0E-05  0.000000  0.000020 
